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Lung cancer continuous to be the leading cause of cancer-related death worldwide. A 
relatively new and effective approach of treating lung cancer is achieved through 
targeting specific molecular alterations in lung cancer cells. While effective molecular 
therapies have been developed and approved in adenocarcinoma of the lung (AC), 
squamous cell lung cancer (SQCLC) and small cell lung cancer (SCLC) still lack any 
approved molecular targets.  
Fibroblast growth factor receptor 1 (FGFR1) is a promising molecular target in 
squamous cell lung cancer and small cell lung cancer subtypes. Clinical trials proved 
the principle of targeting FGFR1 in SQCLC patients harboring FGFR1 amplification. 
However, modest response rates of patients treated with FGFR1 inhibitors suggested 
presence of different layers of resistance, which are either pre-existed in patients or 
developed over the course of treatment.  
In this thesis, I used a cohort of 421 lung cancer primary patient samples to screen 
prevalence of FGFR1 gene amplification among SQCLC and SCLC groups using 
fluorescence in situ hybridization technique (FISH). FGFR1 protein expression was 
screened among AC, SQCLC and SCLC groups using immunohistochemistry (IHC). 
The antibody used in IHC analysis was validated through CRISPR-Cas9 knockout 
system. FGFR1 gene amplification prevalence was compared to protein expression 
in the same set of patients. In order to understand molecular mechanisms that 
underline FGFR1 inhibition resistance in lung cancer cells, I established a model of 
resistant cell lines and compared them to control sensitive cell lines. FGFR1 inhibition 
resistance model consisted of intrinsic resistant lung cancer cell lines, induced 
resistant lung cancer single clones and a mutationally resistant lung cancer cell line. 
Furthermore, mass spectrometric phosphoproteomic analysis was performed to 
compare FGFR1 inhibition resistant cell lines to a control cell line under control and 
inhibition status. MTS viability assay together with other cell viability assays were 
used to validate the co-inhibition effect of FGFR1 alongside with other potential 
molecular targets in FGFR1 resistant lung cancer cells.    
FISH analysis revealed 23% and 8% prevalence of FGFR1 gene amplification among 
SQCLC and SCLC patients. FGFR1 protein was strongly expressed in 9%, 4% and 




correlation between FGFR1 gene amplification and protein expression in lung cancer 
patients. Comparing activated signaling pathways between FGFR1 inhibition 
sensitive and resistant cell lines showed Akt activation as a significant difference 
between the two groups. MTS combination inhibition assays confirmed synergy 
between FGFR1 inhibition and Akt inhibition in intrinsic, induced and constitutively 
active Akt resistant lung cancer cell lines. Mass spectrometric phosphoproteomic 
analysis showed a common resistance pathway in intrinsic and induced resistant 
cells to FGFR1 inhibition. Over phosphorylated CD44, FAK, PAK1, Paxillin and 
Afadin proteins formed the core of the resistance pathway. MTS viability assays 
combined with Chou-Talalay combination index analyses confirmed synergy between 
FGFR1 and PAK1 or FAK inhibition in intrinsic and induced resistant lung cancer cell 
lines to FGFR1 inhibition. Finally, CD44 knockdown combined with FGFR1 inhibition 
showed significant reduction in proliferation of resistant cells compared to single 
treatments.   
To conclude, the current thesis confirmed previously published prevalence of FGFR1 
gene amplification (23% in SQCLC and 8% in SCLC) and protein expression (9% in 
SQCLC, 4% in SCLC and 35% in AC) in lung cancer patients. The thesis revealed 
that FGFR1 gene amplification seems not to be the most accurate selection criteria of 
patients who will benefit from FGFR1 inhibition therapy. Molecular and 
phosphoproteomic analyses alongside with functional validation assays suggested 
that CD44, PAK1, FAK and Akt are promising potential targets that could 
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1.1. Lung cancer 
1.1.1. Prevalence and Mortality 
Lung cancer is the primary cause of cancer-related death worldwide. According to the 
World Health Organization (WHO), 2.1 million cases were newly diagnosed in 2018 
(IARC, 2018). In the same year, lung cancer has killed 1.8 million patients, which 
constituted 18.4% of the total cancer mortality (IARC, 2018). Lung cancer has the 
highest incidence in both sexes compared to other tumors. However, males have 
higher incidence and mortality rate than females. The peak of incidence and mortality 
is at age range of 60 to 75 years in both sexes (Kozielski et al., 2012; Torre et al., 
2016). Bad prognosis and low five-year survival rate are known characteristics of this 
tumor. Survival rates are substantially higher with early diagnosis. In USA, the five-
year survival rate of early stage diagnosis lung cancer is 56%, while this percentage 
falls down to 2-5% in late stage lung cancer (Bozinovski et al., 2016; NIH, 2018).  
Various risk factors have been correlated to lung cancer. Tobacco smoking forms the 
most significant and common risk factor. Long time cigarette smoking decreases life 
expectancy by about ten years (Bruske-Hohlfeld, 2009). Exposure to second hand 
smoking, asbestos silica in industry, arsenic in water, radioactive radon gas and 
some identified susceptibility genes are further validated risk factors (Bruske-
Hohlfeld, 2009; Mao et al., 2016). 
 
1.1.2. Histological classification 
 Lung cancer classification is dynamically improving and updating every few years by 
virtue of continuous research and discovery of new biomarkers that render diagnosis 
and staging of the tumor more specific and allow for more precise treatment. 
Histologically, lung cancer is classified into small cell lung cancer (SCLC, ~15% of 
cases) and non-small cell lung cancer (NSCLC, ~85% of cases) (Figure 1). Non-
small cell lung cancer is further divided into Adenocarcinoma (AC) and squamous cell 
lung cancer (SQCLC) (Woodard et al., 2016). Adenocarcinoma of the lung is the 
most common NSCLC and is characterized by its tubular or acinar structure and 
potential production of mucin. AC usually stains for TTF-1, CK7 and/or Napsin A in 




characterized by intercellular bridges and potential keratinization. Common markers 
for SQCLC are P40, CK5/6 and P63. Squamous cell lung cancer is divided into 
keratinizing, non-keratinizing and basaloid SQCLC (Inamura, 2017; Zheng, 2016). 
Staging of lung cancer is a crucial part of diagnosis. It has a direct effect on 
prognosis as well as treatment strategies. According to the International Association 
for the Study of Lung Cancer (IASLC) and the Tumor, Node and Metastasis system 
(TNM), lung cancer is divided into four main stages based on tumor size and spread 
(Woodard et al., 2016). Stage one is assigned to small tumor sizes below five 
centimeters with no nodal or distal metastasis. Stage two includes tumors between 
three and seven centimeters that can be accompanied by lymph node metastasis but 
without distal metastasis (Sica & Gal, 2012). Stage three tumors are usually larger 
than seven centimeters with mediastinal or subcarinal lymph node metastasis. The 
last and most aggressive stage is number four where the tumor can have different 




Figure 1: Histological types of Lung Cancer. 
 
1.1.3. Squamous cell lung cancer (SQCLC) 
Squamous cell lung cancer is the second most frequent histological type of non-small 
cell lung cancers, which forms about 30% of lung cancer (Figure 1) (Bozinovski et 
al., 2016). Mortality of SQCLC is one of the highest in lung cancer with 400,000 




most frequent NSCLC. This dominance changed when cigarette companies started 
to use filters in their cigarettes. Filters allowed only smaller particles of carcinogens to 
be inhaled, which lead to a rise in adenocarcinoma incidents. However, smoking in its 
direct and indirect forms still makes up 90% of SQCLC cases (Gandara et al., 2015). 
Finally, the spread of awareness about smoking risks decreased SQCLC incidents 
(Gandara et al., 2015).  
SQCLC is usually diagnosed at late stages (stage three or four) due to lack of early 
symptoms. Late diagnosis eliminates choice of surgical intervention or focused 
radiotherapy, which are the treatments of choice for early stages. Patients diagnosed 
with SQCLC, like NSCLC in general, are usually treated with systematic 
chemotherapy. These treatment options can explain the poor five-year survival rate 
of NSCLC of about 2% (Bozinovski et al., 2016).  
 
1.2. Targeted therapies in lung cancer 
1.2.1. Significance of molecular targets  
 Conventional systemic treatments like chemotherapy have been shown to be toxic 
and in some cases tumorigenic in themselves (X. Chen et al., 2017). Toxic off-target 
effects and acquired resistance to conventional therapy led to the urge of developing 
new treatments, which are safer and more specific. Over the years, continuous 
cancer research shed the light on the molecular mechanisms underlying 
tumorigenesis in different tumor entities and sub-types. Heterogeneity of cancer cells 
is now well described in different types of tumors. Differences in molecular 
mechanisms of tumor cells can explain the wide variation in prognosis, response, 
resistance and relapse found in patients diagnosed and treated in the same way. 
Understanding specific molecular mechanisms of a certain cancer type allows not 
only for its accurate diagnosis but also for identifying specific molecular targets 
against it. Molecular targets are on the one hand specific for tumor cells and on the 
other hand vital for tumor growth, survival and progression. Molecular targets in 
cancer therapy can take the form of genes, proteins or components of tumor 
microenvironment (Kummar & Doroshow, 2013). Expression and activation levels of 
these specific targets are usually altered in tumor tissues compared to healthy cells, 




Under this new category of therapy, patients are not only diagnosed for tumor type 
but also for activation/deactivation of specific targets and biomarkers.  
Identification of specific biomarkers or molecular targets is the first step towards 
achieving successful personalized cancer therapy. Biomarkers are usually identified 
through comparing cancer cells to normal cells on different levels. DNA sequencing 
of tumor cells can identify mutated genes, which express mutant proteins that could 
be essential in tumor growth and survival. BRAF mutation is an example of a mutant 
protein (RAF kinase) that leads to overactivation of growth signaling pathways and 
subsequently mutagenesis. Vemurafenib (Zelboraf®) is an approved small molecule 
that can inhibit mutated BRAF, e.g., in melanoma patients (Bollag et al., 2012; NIH, 
2019).  
Discovery of new tumor biomarkers could be based on proteomic screenings. 
Differential analysis of expressed proteins between tumor and healthy cells can lead 
to identification of uniquely overexpressed proteins in tumor cells that are vital for 
their progression. These proteins can then be targeted by monoclonal antibodies. 
Trastuzumab or Herceptin® is the pioneer monoclonal antibody (mAb) and targeted 
therapy in general to be discovered and approved by the US Food and Drug 
Administration (FDA) in 1998. The pioneer antibody is an effective therapy for breast 
cancer in which it binds to Her2 extracellular domain leading to its blockage and 
inhibition of downstream signaling (NIH, 2019; Wilson et al., 2017). 
Detecting chromosomal abnormalities is another method of identifying tumor-specific 
molecular targets. In some cases, chromosomal abnormalities lead to oncogenic 
fusion genes and proteins that can be targeted. Gleevec® is an approved protein 
kinase inhibitor, which inhibits BCR-ABL fusion protein in some myeloid leukemia and 
gastrointestinal tumor patients (NIH, 2019; Somlyai et al., 2017; Van den Abbeele et 
al., 2003). 
 
1.2.2. Receptor tyrosine kinases (RTKs) 
The group of receptor tyrosine kinases (RTKs) consists of 58 receptors that regulate 
vital process in healthy and diseased cells through phosphorylating downstream 
targets. Composition of receptor protein kinases is usually similar in terms of having 




Extracellular domain or N terminal of the receptor is where specific growth factors 
bind to their corresponding receptors. Binding of growth factors initiates receptor 
activation and two receptor monomers start to dimerize/oligomerize. Dimerization 
process starts autophosphorylation and releases autoinhibition of the intracellular 
kinase domain (C terminal). For most RTKs, monomer receptors are an inactive form, 
while dimers are an active form. However, some receptors have a continuous shift 
between inactive monomers and inactive dimers, which are activated and stabilized 
only through ligand binding. (Du & Lovly, 2018)  
In healthy cells, RTKS regulate key processes like cell proliferation, differentiation, 
angiogenesis, tissue repair and survival. Because of this vital role, dysregulation or 
abnormal activity of RTKs is usually involved in pathogenesis of various conditions 
like bone disorders, diabetes and arteriosclerosis (Lemmon & Schlessinger, 2010). In 
tumorigenesis, RTKs are proven to play important roles in tumor initiation and 
progression in the lung, breast, colon and liver (Regad, 2015). Hence, RTKs are 
considered promising molecular targets in cancer therapy.  
 
1.2.3. Targeted therapy in non-small cell lung cancer (NSCLC) 
Late stage NSCLC, where tumor starts to spread into lymph nodes, other parts of the 
lung or distal organs, is routinely treated with systemic chemotherapy. This strategy 
of treatment has lasted for many years without improvement neither in technique nor 
in prognosis of the patients. Discovery and approval of effective targeted drugs in 
tumors like breast cancer and leukemia have led to the urge of discovering molecular 
targets in lung cancer. Adenocarcinoma of the lung was the first histological type of 
lung cancer to achieve successful targeted therapy. Epidermal growth factor (EGFR) 
mutations and Anaplastic Lymphoma Kinase (ALK) gene rearrangements are among 
specific molecular targets in adenocarcinoma. Drugs like gefitinib/erlotinib and 
alectinib/brigatinib that target EGFR mutations and ALK rearrangements, 
respectively, are usually prescribed in advanced NSCLC. Those target specific drugs 
have been successful in improving patients’ overall survival (Figure 2) (Bethune et 
al., 2010; Lin et al., 2018).  
Unlike adenocarcinoma, there are no approved target specific drugs in squamous cell 
lung cancer. This contradiction reflects on the one hand the complexity and 




and efforts to find targetable specific biomarkers. Different genomic abnormalities 
have been described in SQCLC (Perez-Moreno et al., 2012). Phosphoinisitide 3-
kinase C (PI3KC) mutation is the most common potentially targetable genetic 
alteration in SQCLC with prevalence of 33% followed by fibroblast growth factor 
receptor 1 (FGFR1) gene amplification which occurs in 22% of patients (Perez-
Moreno et al., 2012). However, these abnormalities should be further studied and 
understood to estimate the extent of their addictive roles in tumor growth and survival 
(Perez-Moreno et al., 2012; Schultheis et al., 2014; Sholl et al., 2015; L. P. Zhang et 
al., 2015).  
 
 
Figure 2: Prevalence of potential driver mutations in lung cancer. 
 
1.2.4. Fibroblast growth factor receptor 1 (FGFR1) 
Fibroblast growth factor receptor 1 (FGFR1) is a member of an RTK family, which 
consists of four receptors (FGFR1-4) and 22 ligands (FGF1-22). Three 
immunoglobulin-like domains (D1-3) build the extracellular part of the receptor. The 
extracellular domain contains an eight-residue protein (acid box), which binds to D1 
and D2 and is involved in autoinhibition of the receptor. The intracellular part of the 
receptor starts with the juxta-membrane domain followed by two kinase domains on 
each arm of the receptor (Bae et al., 2009). Activation of FGFR1 and FGFRs in 
general, is slightly different from other RTKs. FGFRs require formation of stable 




Dimerization process starts by detachment of the acid box in order to increase affinity 
of receptors to fibroblast growth factors (FGFs) or heparin. Following removal of 
autoinhibition, dimerization of receptor occurs through binding of a bivalent ligand at 
D2 and D3 domains, binding of heparin sulfate and receptor-receptor interaction (Du 
& Lovly, 2018). FGFRs dimerization starts the transformation of the intracellular 
tyrosine domain from an inactive cis-configuration to an active trans-configuration. 
Activated tyrosine domains recruit their downstream targets through their src-
homology-2 domains (SH2) or their phosphotyrosine binding domains (Bae et al., 
2009). Following activation of kinase domains, four main pathways are activated in 
FGFR1 signaling and are responsible for its role in cell growth, maintenance and 
survival. These pathways are RAS/RAF/MEK/MAPK pathway, PI3K/Akt pathway, 
JAK-STAT pathway and PLCγ pathway (Figure 1.3) (Ornitz & Itoh, 2015).  
Dysregulation of FGFR1 signaling can be attributed to different factors. Three main 
genetic abnormalities do lead to overactivation of FGFR1 signaling. Firstly, 
amplification of the gene copy number, which is usually diagnosed by fluorescence in 
situ hybridization (FISH) can lead to protein overexpression and overactivation of 
downstream signaling pathways. Secondly, mutations at extracellular or intracellular 
domains of the receptor can lead to autoactivation and dimerization of the receptor 
without FGFs binding. Finally, genomic abnormalities like FGFR1 gene fusions can 
dimerize and activate the tyrosine kinase domains through binding to the fused 
proteins instead of normal growth factors. Other factors like alterations in noncoding 
regions, transcriptional factor or elevated levels of FGFs in tumor microenvironment 






Figure 3: FGFR1 signaling pathways. 
 
1.3. Targeting FGFR1 in squamous cell lung cancer (SQCLC) 
 Systemic chemotherapies are cytotoxic to fast proliferating cells in the body including 
tumor cells and healthy cells as well (Gronberg et al., 2010; Mittra et al., 2017). Apart 
from their broad activity and side effects, chemotherapies have shown low efficacy in 
advanced cases of NSCLC especially in SQCLC with a median overall survival of 9 
to 11 months (Sholl et al., 2015; Socinski et al., 2012). The aforementioned reasons 
demonstrated the importance of developing targeted therapies for late stage lung 
cancer patients in general and SQCLC patients in particular. As outlined above, 




can lead to dramatic improvement of prognosis even in late stage lung cancer cases. 
Unlike adenocarcinoma, SQCLC lags behind without any approved targeted therapy 
(Tao et al., 2016; Y. C. Zhang et al., 2016).  
Fibroblast growth factor 1 gene is amplified in about 22% of SQCLC patients (Elakad 
et al., 2020; Sabari & Paik, 2017; Sholl et al., 2015). Wide spread of FGFR1 
amplification in SQCLC made it one of the most interesting and studied molecular 
targets in this group (Chae et al., 2017). So far, 19 small molecules tyrosine kinase 
inhibitors (TKIs) that can target and inhibit FGFR1 alongside with other RTKs have 
been developed. Out of these inhibitors, only three inhibitors are specific to FGFR1, 
which are AZD4547 developed by Astrazeneca©, Infigratinib (BGJ398) developed by 
Novartis© and Debio1347 developed by Debiopharm© (Katoh, 2019).  
The tyrosine kinase inhibitors AZD4547 and BGJ398 are found to be highly specific 
FGFR1 inhibitors with IC50 values of less than one nanomolar (Table 1) (Katoh, 
2019). Both of AZD4547 and BGJ398 TKIs have reached phase II clinical trials 
(Katoh, 2019). AZD4547 is considered the most specific second-generation FGFR1 
inhibitor with 1000-fold more potency against FGFR1 than FGFR4. The 
Astrazeneca© inhibitor is a type I inhibitor which binds and blocks the ATP site at the 
kinase domain in the active configuration of the receptor (Tucker et al., 2014). 
 
Table 1: Activity of FGFR1 inhibitors. 
 
 
 Phase II clinical trials of AZD4547 in SQCLC patients with FGFR1 amplification have 




On the other side, BGJ398 has shown 11% partial response in SQCLC with FGFR1 
amplification patients during clinical trials (Nogova et al., 2017). In both studies, a 
group of patients, which formed around 7% has shown very good response with 
significant raise in overall survival. These results have proven the concept of using 
FGFR1 as a molecular target in SQCLC patients. However, the relatively low 
response rate in clinical trials alongside with tumor relapse after initial response, 
revealed a common behavior of resistance against FGFR1 inhibitors (Paik et al., 
2017). 
Studies have attempted to understand reasons and mechanisms of resistance 
against FGFR1 inhibition. A possible reason for resistance could be co-amplified 
genes, which are located on the same region of chromosome 8 like ZNF708 and 
RAB11FIP1 genes (Kwek et al., 2009). Another reason, which could result in bad 
response to FGFR1 inhibition is the inconsistent correlation between FGFR1 gene 
amplification and protein expression levels in lung cancer patients (Elakad et al., 
2020; Seo et al., 2014; von Massenhausen et al., 2013; Wynes et al., 2014). 
However, the most studied mechanism of resistance to FGFR1 inhibitors is the 
activation of a bypath signaling pathway/pathways that compensate for the inhibited 
pathway. Bypath resistance pathways could originate from previously activated 
pathways (intrinsic resistance) or newly activated pathways due to long exposure to 
the inhibitors (acquired resistance) (Nogova et al., 2017; Paik et al., 2017).  
Current studies focus on understanding molecular mechanisms underlying both types 
of resistance (intrinsic and acquired) in order to find targets that can sensitize cells to 
FGFR1 inhibition. In 2016, Kim and colleagues have shown that Met kinase was 
overexpressed in a resistant clone developed from a sensitive cell line to FGFR1 
inhibitors. They have concluded that combining FGFR1 inhibitors with Met inhibitors 
can re-sensitize resistant cells (S. M. Kim et al., 2016). In 2017, Lin and colleagues 
have found that c-Myc degradation was an essential step for FGFR/MEK-ERK 
pathway inhibition. Disruption or mutation of c-Myc can result in resistance to FGFR1 
inhibitors in lung cancer cell lines (H. Liu et al., 2017). NRAS amplification has been 
shown to be able to reactivate inhibited FGFR1/MAPK pathway in H1581 lung cancer 
cell line (Malchers et al., 2017). 
Multiple studies tried to understand mechanisms of resistance to FGFR1 inhibition in 




the small size of models used in these studies, usually two or three cell lines, renders 
the findings very specific to the cell lines used and not to the general FGFR1 
inhibition resistance mechanisms (Bockorny et al., 2018; Fumarola et al., 2017; 
Malchers et al., 2017). The aforementioned reason can also explain the versatile, and 
frequently contradictory findings of FGFR1 inhibition resistance in lung cancer cells. 
Literature studies have not compared intrinsic to acquired resistance of FGFR1 
inhibition in lung cancer. Finally, until now, no phosphoproteomic or global proteomic 
analysis has compared sensitive and resistant cells to FGFR1 inhibition in lung 
cancer. Consequently, more efforts should be exerted in this direction in order to 
understand the exact mechanisms of resistance and to find effective targets that 
sensitize resistant SQCLC cells to FGFR1 inhibition. 
 
1.4. Proteomic analysis  
1.4.1. Proteomic analysis in cancer research 
Cancer is a highly heterogenic disease that requires continuous invention and 
upgrading of high-resolution analytical tools to study. New analytical methods give us 
clearer, sometimes completely new, view on deep mechanisms of tumorigenesis. 
Over the years, genomic analysis through DNA sequencing was the standard tool to 
screen differences between healthy and cancer cells (Craig et al., 2016; Kamps et 
al., 2017). DNA sequencing is a robust method to screen genomic mutations; 
however, aberrant protein expression and signaling pathways overactivation can 
trigger tumorigenesis, too (Kosti et al., 2016; Raina et al., 2011). Measuring levels of 
genes end products gives us new insights about direct effectors of cell signaling and 
hence tumorigenesis (He et al., 2012; Panis et al., 2019). Applying proteomic 
screening techniques in cancer research is anticipated to help us finding new and 
accurate tumor biomarkers and prognostic factors for cancer treatment (Cho, 2017; 
Shruthi et al., 2016). In 2019, Suhas Vasaiker and his colleagues have presented a 
large scale proteogenomic study conducted on 110 human colon cancer patient 
samples compared to healthy tissue samples. The study has revealed the 
significance of proteomic analyses, particularly phosphoproteomic analyses, in not 
only validating and correcting genetically identified molecular targets but also 





The necessity of robust tools for large-scale proteomic analysis has ignited the 
development and improvements in mass spectrometry (MS) (Tyers & Mann, 2003; Z. 
Zhang et al., 2014).  
Mass spectrometry is the most powerful and robust tool available to analyze proteins 
from different biological samples with high throughput, low cost and high 
reproducibility (Nilsson et al., 2010). Mass Spectrometry can not only identify and 
quantify proteins, but also identify their interaction and posttranslational modification 
(Cho, 2017). Over the past few years, mass spectrometry was prone to extensive 
research and development, which led to different machines and protocols that are 
currently available (Olshina & Sharon, 2016). Generally, two main analysis strategies 
exist when analyzing proteins through mass spectrometry. The first strategy is called 
top-down analysis in which proteins of usually known identity are collected as a 
whole and measured. Top-down strategy is useful to identify posttranslational 
modifications in proteins of known sequence (Kellie et al., 2010; Olshina & Sharon, 
2016). The second strategy, that happens to be more common, is the bottom-up 
where all the proteins are purified from cells then digested and run through MS (Kellie 
et al., 2010; Olshina & Sharon, 2016).  
Posttranslational modification (PTM) is an important regulatory mechanism of 
proteins. Phosphorylation, methylation, ubiquitination and glycosylation are common 
forms of modifications among more than 400 other PTMs identified (Minguez et al., 
2012). Modification of expressed proteins regulates their activity through adjusting 
their localization, stability, folding, conformation and function (Saraswathy & 
Ramalingam, 2011). Identification and quantification of PTM add another level of 
information when comparing healthy to malignant cells. Quantifying functionally 
active proteins is more informative and of higher value than comparing total active 
and inactive expressed proteins. However, modified proteins with specific 
modifications are usually many folds less common than their unmodified forms. 
Therefore, enrichment for peptides with specific modifications is an important step 
prior to identification and quantification. (Khoury et al., 2011). 
Phosphorylation is the most studied posttranslational modification, which regulates 
most of cellular processes (Nesverova & Tornroth-Horsefield, 2019). Protein 
phosphorylation is a reversible process where a phosphate group is added to a side 




tight regulation through a group of kinases and phosphatases in the cell. With more 
than 10,000 identified phosphorylation sites, phosphorylation is widespread through 
the proteome where 30-75% of the proteome is phosphorylated at any time point 
(Drake et al., 2016; Ficarro et al., 2002; Saraswathy & Ramalingam, 2011). 
Phosphoproteomic analysis using mass spectrometry is a robust method to identify 
and quantify phosphorylated peptides among the cellular proteome. This robust tool 
empowers the study of molecular mechanisms of tumorigenesis and allows the 
discovery of new tumor biomarkers and therapeutic targets like ACTN4 and 
ARFGEF2 in Burkitt’s lymphoma (Corso et al., 2016). Enrichment for 
phosphopeptides usually depend on phospho-specific antibodies or chromatography 
techniques like immobilized metal affinity (IMAC) and Titanium Dioxide (TiO2) (Lopez 
et al., 2012). 
 
1.4.2. Liquid chromatography-coupled electrospray ionization mass 
spectrometry (LC-MS/MS) 
In order to analyze any sample on mass spectrometry, samples have to go through 
five main steps. The first step is sample preparation followed by fractionalization, 
ionization of peptides, detection and then finally data analysis. Sample preparation 
includes culturing of target cells; this may include treatment with specific stimulators 
or inhibitors, which depends on the study. After culturing, cells are lysed with specific 
lysis buffers in order to extract the protein content. Lysis buffers’ properties like pH 
values and percentages of detergents and proteases inhibitors are crucial for 
accurate and high yield experiments (Haupl et al., 2019; Stokes et al., 2012). Lysates 
are then digested with enzymes to produce peptides of smaller sizes and with 
specific properties. Trypsin is the most common digestion enzyme, which cuts 
peptides at the lysine or arginine carboxyl side. Peptides produced from trypsin 
digestion (tryptic peptides) are very complex and highly concentrated. Accurate 
acquisition and sensitive measurement of MS need the samples to be fractionized 
into less condense and less concentrated amounts. Liquid chromatography (LC) 
offers a convenient and efficient method to fractionize complex peptides into more 
simple peptides with properties similar to those needed for mass spectrometry 
(Ligon, 2001). Liquid chromatography coupled online to MS (LC-MS) is a common 




measurements at femtomole level (Figure 4) (Haupl et al., 2019; Ligon, 2001; Stokes 
et al., 2012).  
To enable identification and quantification, peptides have to be ionized into charged 
ions. Peptides are transformed into detectable ions through one of different ionization 
techniques. Electronspray ionization (ESI) and matrix-assisted laser desorption 
(MALDI) are the two most common ionization techniques. In ESI, peptides dissolved 
in solution are sprayed under high voltage and negative pressure forming tiny 
charged droplets or ions. Ions on this level usually are multiply charged and are 
detected by an analyzer as mas over charge or Thomson value (m/z) (Ho et al., 
2003). Specific ions are chosen as precursors for further fragmentation into singly 
charged ions, which are then detected (second MS or MS/MS). Analysis of MS data 
depends on comparing masses of measured peptides to databases. These 
databases contain all theoretical peptide masses resulted from virtual tryptic 
digestion of the whole proteome (Haupl et al., 2019; Ho et al., 2003; Stokes et al., 
2012).  
 
1.5. Stable Isotope Labeling with Amino acids (SILAC) labeling 
Mass spectrometry is not inherently a quantitative method but rather a qualitative 
method that is able to detect peptides and hence identify proteins. Therefore, MS 
analysis is usually coupled to other tools that can make it a quantitative tool. 
Quantification using MS is achievable through comparing quantities of peptides 
between two samples. Those samples can be labelled or label free and can be used 
for relative or absolute quantification (Ankney et al., 2018). Sample labeling can take 
metabolic or chemical form. Stable Isotope Labeling with Amino acids (SILAC) is 
considered a common and straightforward labeling method, which enables relative 
quantification of different samples within the same MS analysis (Ankney et al., 2018). 
The method depends on feeding cells with special culture medium containing heavy 
amino acids instead of normal amino acids. Following multiple cycles of culture, cells 
incorporate heavy amino acids in their proteins and become distinguishable from 
their normal light counterparts. Heavily labelled proteins are mixed with light/normal 
proteins and measured together through MS (X. Wang et al., 2018). Arginine 6/10 
and Lysine 4/8 are examples of heavy amino acids that are commonly used (Figure 














1.6. Aim of the Study 
For decades lung cancer is the leading type of cancer in terms of incident rates and 
mortality. Molecular therapy is considered a promising and effective way to target 
lung cancer cells. Unlike adenocarcinoma of the lung, squamous cell lung cancer and 
small cell lung cancer subgroups lack any approved molecular targets. Fibroblast 
growth factor receptor 1 (FGFR1) is considered an encouraging new target due to its 
high prevalence of amplification in SQCLC and SCLC patients and efficacy in clinical 
trials. However, a high proportion of lung cancer patients with FGFR1 amplification 
have shown initial resistance or acquired resistance to FGFR1 targeted therapy.  
The aim of the current thesis is to improve selection criteria for patients who will 
benefit from FGFR1 targeted therapy and to investigate and confront mechanisms of 
resistance to FGFR1 inhibition in lung cancer cells. The key objectives are:   
a. Screening prevalence of FGFR1 gene amplification and protein expression in 
lung cancer patient tissue samples using fluorescence in situ hybridization 
(FISH) and immunohistochemistry (IHC), respectively. 
b. Examining correlation between FGFR1 gene amplification and protein 
expression in lung cancer patient tissue samples to help improving selection 
criteria for patients who benefit from FGFR1 targeted therapy. 
c. Investigating intrinsic and induced mechanisms and signaling pathways of 
resistance to FGFR1 inhibition in lung cancer cells using phosphoproteomic 
mass spectrometric analysis. 
d. Characterizing and functional validating new molecular targets, which can 
sensitize lung cancer resistant cells to FGFR1 inhibition therapy. 








Autoclave Systec VX 100 
Autostainerlink48 Agilent technologies, California, 
USA 
Bacterial incubator, Heraeus instruments 
function line 
Thermo Fischer Scientific, 
Waltham, USA 
Bacterial shaker, orbital shaker VWR, Pennsylvania, USA 
Eppendorf Centrifuge 5424  Eppendorf, Hamburg, Germany 
Eppendorf Centrifuge 5430R Eppendorf, Hamburg, Germany 
FACSAria sorter BD, California, USA 
Fusion Fx, peQlab VILBER 
Genetic analyzser 3500 Applied Biosystems, 
Massachusetts, USA 
Herasafe, biological culture hood, Heraeus 
instruments 
Thermo Fischer Scientific, 
Waltham, USA 
MiSeq® System, SY-410-1003 Illumnia Inc., USA 
Mr. Frosty™ Gefrierbehälter Thermo Fischer Scientific, 
Waltham, USA 
Muse Guava cell analyzer Luminex 
Nanodrop 2000/c Thermo Fischer Scientific, 
Waltham, USA 
Plate reader, TECAN 200M pro TECAN, maennedorf, 
Switzerland 
Primovert Microscope CARL ZEISS, Oberochen, 
Germany 
Privileg 8018e microwave Privileg, Stuttgart, Germany 
Q Exactive™ HF Hybrid Quadrupol-
Orbitrap™ Massenspektrometer 
Thermo Fischer Scientific, 
Waltham, USA 
QIAxcel QIAGEN, Venlo, Netherlands  
Sonicator, Bandelin Sonopuls HD70 Bandelin, Berlin, Germany 




Speed Vacuum concentrator Thermo Fischer Scientific, 
Waltham, USA 
Thermocycler, peqSTAR Peqlab 
Trans-Blot Turbo Bio-Rad, Hercules, USA 
Tubes vortex, schuett labortechnik LABO 
UltiMate™ 3000 RSLCnano System Thermo Fischer Scientific, 
Waltham, USA 
VP2000 processor system  Abbott Molecular, Wiesbaden, 
Germany 
WTC binder Cell lines incubator, Binder 
ZOE fluorescent cell imager Bio-Rad, Hercules, USA 
 
2.1.2. Antibodies 
Antibody Technique Dilution Supplier 
Akt #9272 WB 1:10000 Cell Signaling Technology 
Europe, Frankfurt am 
Main, Germany 
ERK, (Erk1/2) Antibody 
#9102 
WB 1:10000 Cell Signaling Technology 
Europe, Frankfurt am 
Main, Germany 
FGFR1 (D8E4) #9740 WB, IHC 1:10000 Cell Signaling Technology 




WB, IHC 1:5000 Abcam, Germany 
MEK1/2 Antibody #9122 WB 1:10000 Cell Signaling Technology 
Europe, Frankfurt am 
Main, Germany 
PARK7 (ab18257) WB 1:10000 Abcam, Germany 
Phospho-Akt (Ser473) 
#9271 
WB, IHC 1:10000 Cell Signaling Technology 
Europe, Frankfurt am 
Main, Germany 






WB 1:10000 Cell Signaling Technology 





IHC 1:100 Abcam, Germany 
Phospho-CD44 (pSer706) WB 1:10000 Sigma-Aldrich Co., St. 
Louis, USA 
Phospho-ERK(C33E10) 
Rabbit mAb #3192 
WB 1:10000 Cell Signaling Technology 




WB 1:10000 Cell Signaling Technology 




WB 1:10000 Cell Signaling Technology 




WB 1:10000 Cell Signaling Technology 




#2601    
WB 1:10000 Cell Signaling Technology 
Europe, Frankfurt am 
Main, Germany 
Phospho-PI3 Kinase p85 
(Tyr458)/p55 (Tyr199) 
#4228 
WB 1:10000 Cell Signaling Technology 




WB 1:10000 Cell Signaling Technology 




WB 1:10000 Agilent, California, USA 
Polyclonal Goat anti-rabbit, 
HRP 
WB 1:10000 Agilent, California, USA 




Propidium Iodide stain FACS 10 
μg/mL 
Thermo Fischer Scientific, 
Waltham, USA 
PTEN (138G6) Rabbit 
mAb #9559 
WB 1:10000 Cell Signaling Technology 
Europe, Frankfurt am 
Main, Germany 
PTMScan® Phospho-
Tyrosine Rabbit mAb (P-




 Cell Signaling Technology 
Europe, Frankfurt am 
Main, Germany 
ZytoLight SPEC 
FGFR1/CEN 8  
FISH  ZytoVision, Bremerhaven, 
Germany 
 
2.1.3. Cell lines 
Cell line Culture medium Supplier 
DMS114, CRL-2066, 
human SCLC 
RPMI 1640, 10% FCS, 1% 








DMS-53, human SCLC Waymouth's MB 752/1 Medium, 





EBC-1, human SQCLC RPMI 1640, 10% FCS, 1% 
Glutamine and 1% penecillin-
streptomycin 






H1339, human SCLC RPMI 1640, 10% FCS, 1% 
Glutamine and 1% penecillin-
streptomycin 
ATCC, Wesel 
H1581, human large cell 
LC 
RPMI 1640/DMEM/F12 1:1, 10% 
FCS, 1% Glutamine and 1% 
AddexBio 
Technologies, 





H1703, human SQCLC RPMI 1640, 10% FCS, 1% 







RPMI 1640, 10% FCS, 1% 
Glutamine and 1% penecillin-
streptomycin 
ATCC, Wesel 
H226, human SQCLC RPMI 1640, 10% FCS, 1% 





H-520, HTB-182, human 
SQCLC 
RPMI 1640, 10% FCS, 1% 
Glutamine and 1% penecillin-
streptomycin 
ATCC, Wesel 
H69, human SCLC RPMI 1640, 10% FCS, 1% 
Glutamine and 1% penecillin-
streptomycin 
ATCC, Wesel 
H82, HTB-175, human 
SCLC 
RPMI 1640, 10% FCS, 1% 
Glutamine and 1% penecillin-
streptomycin 
ATCC, Wesel 
HCC-15, ACC 496, 
human SQCLC 
RPMI 1640, 10% FCS, 1% 







HCC33, human SCLC RPMI 1640, 10% FCS, 1% 







LCLC103H, human large 
cell LC 
RPMI 1640, 10% FCS, 1% 











LK-2, human SQCLC RPMI 1640, 10% FCS, 1% 
Glutamine and 1% penecillin-
streptomycin 








RPMI 1640, 10% FCS, 1% 
Glutamine and 1% penecillin-
streptomycin 
ATCC, Wesel 
OH3,  CVCL_A766, 
human SCLC 
RPMI 1640, 10% FCS, 1% 
Glutamine and 1% penecillin-
streptomycin 
ATCC, Wesel 
SCLC21H, human SCLC RPMI 1640, 10% FCS, 1% 
Glutamine and 1% penecillin-
streptomycin 
ATCC, Wesel 
SHP77, human SCLC RPMI 1640, 10% FCS, 1& 





EMEM (C0005-01), 10% FCS, 1% 





SW2, human SCLC RPMI 1640, 10% FCS, 1% 




2.1.4. siRNAs and guide RNAs 
siRNA/gRNA Supplier 
AllStars Neg. Control siRNA (20 nmol) Cat 
No./ID: 1027281 
Qiagen GmbH, Hilden 
Crispr, fwd, primer: 
GGGGCTCTTACCCCAATGTT 
Eurofins, Ebersberg, Germany 
Crispr, rev, primer: Eurofins, Ebersberg, Germany 







Eurofins, Ebersberg, Germany 
gRNApast1rev5’-
AAACCCTGGCTACACTGGTGCTCCC-3’ 
Eurofins, Ebersberg, Germany 
gRNApre1fwd 5’-P-
CACCGTTCCCAGGTCCCCTAAGAGG-3’ 
Eurofins, Ebersberg, Germany 
gRNApre1rev 5’-
AAACCCTCTTAGGGGACCTGGGAAC-3’ 
Eurofins, Ebersberg, Germany 
Hs_FGFR1_6 FlexiTube siRNA Qiagen GmbH, Hilden 
Hs_FGFR1_7 FlexiTube siRNA Qiagen GmbH, Hilden 
U6 primer, 
5’GAGGGCCTATTTCCCATGATTCC-3’ 
Eurofins, Ebersberg, Germany 




1036 pcDNA3 Myr HA Akt1 (Plasmid #9008), Addgene 
1436 pcDNA3 Flag HA (Plasmid #10792), Addgene 
pSpCas9(BB)-2A-GFP (PX458) (Plasmid #48138), Addgene 
pU6-(BbsI)_CBh-Cas9-T2A-mCherry (Plasmid #64324), Addgene 
 
2.1.6. Buffers and media 
Unless otherwise stated, buffers and media were dissolved in distilled water (ddH2O). 
LB growth media were autoclaved at 125 °C then stored at 4 °C. Culture media 
serums were heat deactivated at 56 °C then stored at -20 °C. Glutamine and 
penicillin-streptomycin aliquots were stored at -20 °C. Buffers and media were stored 
at room temperature, unless otherwise stated. 
Reagent Composition 
70% Ethanol 700 mL Ethanol (99.9%) in 1 L ddH2O 
Blocking buffer 5% milk powder in TBS-T 




DMEM 10% FCS, 1% Penstrip & 1% glutamine 
Freezing medium 5% DMSO in FCS 
Global proteome lysis buffer 50mM Tris-HCL PH 7,5, 150mM NACL, 1mM 
EDTA-disodium salt, 1% (v/v) NP-40 , 0.1% 
(w/v) Na-deoxycholate, 1 tab Roche complete 
protease inhibitor cocktail, 5mM ß-
glycerophosphate, 5mM NaF, 1mM Na-
orthovandate, 10mM N-ethylmaleimide (NEM) 
and LC-MS grade water 
Heavy SILAC medium SILAC medium, 50mL dialyzed FCS, 5mL 
glutamine, 5mL Penstrip, 5,5mL Na-pyruvate 
solution, 5,5mL ArgH & 5,5mL LysH 
LB- Agar 15 g/L Agar-Agar in LB medium 
LB medium 25 g LB medium in 1 L dH2O 
Loading buffer (1:1/3) 500/250 µL 2x/4x Laemmli Sample Buffer, 
500/750 µL 2-Mercaptoethanol 
Medium SILAC medium SILAC medium, 50mL dialyzed FCS, 5mL 
glutamine, 5mL Penstrip, 5,5mL Na-pyruvate 
solution, 5,5mL ArgM & 5,5mL LysM 
NP40 Lysis buffer 50 mM Tris/HCl (pH 7.6), 150 mM NaCl, 5 mM 
NaF, 1% NP-40 
PBS 9.55 g/L PBS Dulbecco in ddH2O 
Ponceau 0.5 g Ponceau, 5 mL 100% glacial acetic acid 
in 500 mL with ddH2O 
pYome lysis buffer 20mM HEPES PH8, 2.5mM Sodium 
pyrophosphate tetrabasic decahydrate, 1mM 
β-Glycerophosphate disodium salt hydrate, 
1mM Naorthovandate NaVO4, 8M Urea, LC-
MS grade water 
RPMI-1640 10% FCS, 1% Penstrip & 1% glutamine 
TBE buffer 100 mL 10X TBE buffer in 1 L ddH2O 
TBS 4.24 g Tris, 292.7 g NaCl, 26 g Tris-HCl 
solved in 1 L ddH2O 




TBS-T 1 L 10X TBS, 9 L ddH2O and 10 mL Tween-20 
Waymouth's MB 752/1 10% FCS, 1% Penstrip & 1% glutamine 
Westernblotting running buffer 100 mL 10X Tris/Glycine/SDS Buffer in 1 L 
ddH2O 
 
2.1.7. Reagents and kits 
Reagent Supplier 
10X Tango Buffer Thermo Fischer Scientific, Waltham, 
USA 
10X Tango buffer Thermo Fischer Scientific, Waltham, 
USA 
10X Tris-Glycine-SDS Buffer Bio-Rad, Feldkirchen, Germany 
2x Laemmli Sample Buffer Bio-Rad, Feldkirchen, Germany 
4x Laemmli Sample Buffer Bio-Rad, Feldkirchen, Germany 
6X loading Dye Thermo Fischer Scientific, Waltham, 
USA 
Agar-Agar Carl Roth GmbH & Co. KG, Karlsruhe 
Ambion® DEPC-treated water Invitrogen, Massachusetts, USA 
Ampicillin AppliChem GmbH, Darmstadt 
Ampicillin Gibco, Massachusetts, USA 
Archer® FusionPlex® CTL Panel Illumnia, San Diego, California, USA 
ATP (10mM) Thermo Fischer Scientific, Waltham, 
USA 
BigDye XTerminator™ Purification Kit Applied Biosystems, Massachusetts, 
USA 
Buffer O Thermo Fischer Scientific, Waltham, 
USA 
Celltiter 96 Aqueous one solution Thermo Fischer Scientific, Waltham, 
USA 
DAB Substrate Kit Agilent Technologies, California, USA 
DC™ Protein Assay Bio-Rad, Feldkirchen, Germany 
Dh5alpha competent E. coli Thermo Fischer Scientific, Waltham, 
USA 




Dialyzed fetal bovine serum (dialyzed 
FbS) 
Gibco, Massachusetts, USA 
DMEM medium Gibco, Massachusetts, USA 
dNTPs New England Biolabs GmbH, Frankfurt 
am Main, Germany 
DTT (10mM) Thermo Fischer Scientific, Waltham, 
USA 
EDTA Merck, Darmstadt, Germany 
EnVision Flex Target Retrieval Solution, 
pH high or low 
Agilent Technologies, California, USA 
ExoSAP-IT Express PCR Cleanup 
Reagents 
Thermo Fischer Scientific, Waltham, 
USA 
Fast Digest BbsI (Bpil) New England Biolabs GmbH, Frankfurt 
am Main, Germany 
FastDigest BbsI Thermo Fischer Scientific, Waltham, 
USA 
FastDigest Buffer (10X) Thermo Fischer Scientific, Waltham, 
USA 
FastDigest Green Buffer (10X) Thermo Fischer Scientific, Waltham, 
USA 
Fetal bovine serum (FbS), quantified Hi Gibco, Massachusetts, USA 
Glutamine Gibco, Massachusetts, USA 
Hipercfect QIAGEN, Venlo, Netherlands 
HistoGel™ Thermo Fischer Scientific, Waltham, 
USA 
Lauryl-β-D-maltoside Merck, Darmstadt, Germany 
LB medium Carl Roth GmbH & Co. KG, Karlsruhe 
Lipofectamine 3000 Invitrogen, Massachusetts, USA 
L-LYSINE:2HCL (13C6, 99%; 15N2, 
99%), CNLM-291-H-0.25 (Lys H) 
Cambridge Isotope Laboratories, Inc., 
USA 
Milk powder Carl Roth GmbH & Co. KG, Karlsruhe 
Mini-PROTEAN, Precast Gels Bio-Rad, Feldkirchen, Germany 
Na-pyruvate solution, 11360070 Gibco, Massachusetts, USA 




Nitrocellulose membranes (Trans-Blot 
Bio-Rad Laboratories 
Bio-Rad, Hercules, USA 
P3000 reagent Invitrogen, Massachusetts, USA 
PageRuler, Prestained 10 to 250 kDa Thermo Fischer Scientific, Waltham, 
USA 
Penicillin/Streptomycin (10,000 U/mL) Gibco, Massachusetts, USA 
Penicillin/Streptomycin, 15140163 Gibco, Massachusetts, USA 
Phosphate buffered saline (PBS) 
Dulbecco 
Merck, Darmstadt, Germany 
Pierce™ BCA Protein Assay Kit Thermo Fischer Scientific, Waltham, 
USA 
Purgene® Core Kit A QIAGEN, Venlo, Netherlands 
QIAquick PCR Purification Kit QIAGEN, Venlo, Netherlands 
Reblot Plus Strong antibody stripping 
solution 
Merck, Darmstadt, Germany 
Rnase inhibitor20 U/µL Thermo Fischer Scientific, Waltham, 
USA 
RPMI-1640 medium Gibco, Massachusetts, USA 
SILAC RPMI 1640 medium Gibco, Massachusetts, USA 
StarPure AGAROSE Low EEO 
Standard 
STARLAB GmbH, Ahrensburg, 
Germany 
T4 ligase New England Biolabs GmbH, Frankfurt 
am Main, Germany 
Taq DNA polymerase New England Biolabs GmbH, Frankfurt 
am Main, Germany 
Western Plus-ECL PerkinElmer, USA 
Waymouth's MB 752/1 medium Thermo Fischer Scientific, Waltham, 
USA 
Ethanol (99.9%) Merck, Darmstadt, Germany 
L-ARGININE:HCL (13C6, 99%), CLM-
2265-H-0.1, Arg6 (Arg M) 
Cambridge Isotope Laboratories, Inc., 
USA 
L-ARGININE:HCL (13C6, 99%; 15N4, 
99%), CNLM-539-H-0.1 (Arg H) 
Cambridge Isotope Laboratories, Inc., 
USA 




0.05% Trypsin-EDTA, Gibco Gibco, Massachusetts, USA 
L-LYSINE:2HCL (4,4,5,5-D4, 96-98%), 
DLM-2640-0.25 (Lys M) 
Cambridge Isotope Laboratories, Inc., 
USA 
BigDye™ Terminator v1.1 Cycle 
Sequencing Kit 




Inhibitor Concentration Supplier 
AZD4547 0.003 µM -7.5 µM Selleckchem, Munich, Germany 
AZD5363 0.5 µM - 35 µM Selleckchem, Munich, Germany 
BGJ398 0.003 µM -7.5 µM Selleckchem, Munich, Germany 
FRAX597 0.01µM -10 µM Selleckchem, Munich, Germany 
IPA-3 0.01 µM -30 µM Selleckchem, Munich, Germany 




10 mL and 50 mL tubes Cellstar, greiner bio-one, Germany 
10µL, 10µL & 1000µL filter/tips SARSTEDT, Nümbrecht, Germany 
10CM culture dishes Cellstar, greiner bio-one, Germany 
12-well plates Cellstar, greiner bio-one, Germany 
1mL, 5mL, 10mL & 25mL pipettes SARSTEDT, Nümbrecht, Germany 
24-well plates Cellstar, greiner bio-one, Germany 
6-well plates Cellstar, greiner bio-one, Germany 
96-well plates Cellstar, greiner bio-one, Germany 
Cells scraper 25 CM SARSTEDT, Nümbrecht, Germany 
Cryopure SARSTEDT, Nümbrecht, Germany 
Disposable syringe, 10 ml SARSTEDT, Nümbrecht, Germany 
Disposable syringe, 2 ml Luer SARSTEDT, Nümbrecht, Germany 
DNA LoBind Tubes Eppendorf, Hamburg, Germany 




Muse® Count & Viability Assay kit Merck, Darmstadt, Germany 
QIAGEN Plasmid Midi Kit QIAGEN, Venlo, Netherlands 
QIAprep Spin Miniprep Kit QIAGEN, Venlo, Netherlands 
T175 culture flasks SARSTEDT, Nümbrecht, Germany 
T25 culture flasks SARSTEDT, Nümbrecht, Germany 
T75 culture flasks SARSTEDT, Nümbrecht, Germany 
Tissue embedding plastic cassettes Merck, Darmstadt, Germany 
Trans-Blot® Turbo™ RTA Mini 
Nitrocellulose Transfer Kit 
Bio-Rad, Feldkirchen, Germany 
Tube 30ml, 84x30mm, PP SARSTEDT, Nümbrecht, Germany 
Tube 7ml, 50x16mm, PS SARSTEDT, Nümbrecht, Germany 
1.5 and 2 mL microtubes SARSTEDT, Nümbrecht, Germany 
Microfilters, 0.2µM, 0.45µM SARSTEDT, Nümbrecht, Germany 
 
2.1.10. Chemical reagents 
Reagent Supplier 
2-Mercaptoethanol Carl Roth GmbH & Co. KG, Karlsruhe 
Bovine Serum Albumin (BSA) Carl Roth GmbH & Co. KG, Karlsruhe 
EDTA-disodium salt Carl Roth GmbH & Co. KG, Karlsruhe 
Ethidium bromide Carl Roth GmbH & Co. KG, Karlsruhe 
G418 (Geneticin) InvivoGen, California, USA 
Glacial acetic acid Merck, Darmstadt, Germany 
HEPES Sigma-Aldrich Co., St. Louis, USA 
Isopropanol (100%) Merck, Darmstadt, Germany 
Kanamycin Gibco, Massachusetts, USA 
LC-MS grade water Carl Roth GmbH & Co. KG, Karlsruhe 
Na4P2O7 Carl Roth GmbH & Co. KG, Karlsruhe 
NaCl Carl Roth GmbH & Co. KG, Karlsruhe 
Na-deoxycholate Carl Roth GmbH & Co. KG, Karlsruhe 
Naorthovandate Sigma-Aldrich Co., St. Louis, USA 
Na-orthovandate Carl Roth GmbH & Co. KG, Karlsruhe 




N-ethylmaleimide Carl Roth GmbH & Co. KG, Karlsruhe 
NP-40 Carl Roth GmbH & Co. KG, Karlsruhe 
Ponceau S AppliChem GmbH, Darmstadt, 
Germany 
Roche complete protease inhibitor 
cocktail (cOmplete™) 
Merck, Darmstadt, Germany 
Sodium Chloride (NaCl) Carl Roth GmbH & Co. KG, Karlsruhe 
Sodium dodecyl sulfate (SDS) Carl Roth GmbH & Co. KG, Karlsruhe 
Sodium fluoride (NaF) Carl Roth GmbH & Co. KG, Karlsruhe 
Sodium pyrophosphate tetrabasic 
decahydrate 
Carl Roth GmbH & Co. KG, Karlsruhe 
ß-glycerophosphate Carl Roth GmbH & Co. KG, Karlsruhe 
TRIS Carl Roth GmbH & Co. KG, Karlsruhe 
TRIS-hydrochloride Carl Roth GmbH & Co. KG, Karlsruhe 
Tween®20 AppliChem GmbH, Darmstadt, 
Germany 
Urea Sigma-Aldrich Co., St. Louis, USA 
β-Glycerophosphate disodium salt 
hydrate 




3500 data collection software 3 Applied Biosystems, Massachusetts, 
USA 
Adobe Photoshop 7.0 Adobe Systems Inc. San Jose, USA 
Cistrome CRISPR Scan database http://cistrome.org/SSC/  
CRISPR tefor database http://crispor.tefor.net/crispor.py  
Endnote X9 Clarivate analytics, Philadelphia, USA 
Geneious prime 2019 https://www.geneious.com  
Graphpad Prism 7 for windows GraphPad Software, La Jolla 
California USA, www.graphpad.com” 




ImageJ 1.8 Image J, Schneider, C. A.; Rasband, 
W. S. & Eliceiri, K. W. (2012), "NIH 
Image to ImageJ: 25 years of image 
analysis", Nature methods 9(7): 671-
675 





ZHANG LAB Guide Design Resources https://zlab.bio/guide-design-
resources 





2.2.1. Patients tissue samples 
2.2.1.1. Tissue samples collection 
Tissue samples were collected from lung cancer patients through surgical resections. 
Resections were held by Department of Thoracic Surgery at the University Medical 
Center of Goettingen, Germany. The collection and usage of patient tissue samples 
were approved by the Ethics Committee at the University Medical Center of 
Goettingen (#1-2-08). All patients included in this study have been informed and 
given consent. Collection of samples and experiments have been carried out 
according to declaration of Helsinki as well as institutional, state and federal 
guidelines. 
 
2.2.1.2. Cell block 
Cell blocks were prepared according to a published protocol (Varsegi & Shidham, 
2009). Cell lines were seeded in T-175 culture flasks and harvested when they 
reached 80% confluency. Cells were washed once with PBS, centrifuged at 2000 
RPM for five minutes and placed in a flat bottom 7 mL glass tube (small tube) inside 
a 30 mL plastic tube (carrier tube) then centrifuged once again at 2000 RPM for five 
minutes. HistoGel (Thermo Scientific) was prepared through heating for 30 seconds 
in microwave. Cell pellets were re-suspended in 1 mL warm Histogel. One piece of 
AV-marker was immersed in each gel/cells sample in order to mark the location and 
layer (depth) of cells inside the blocks. AV-marker is used in cell blocks preparation in 
order to detect the location and depth of cell pellets while cutting the paraffin blocks. 
Markers were prepared as described before (Varsegi & Shidham, 2009). Shortly, AV-
markers were set up through collecting small pieces of raw banana peels with 
dimensions of about 2x2x2 mm then immersing them in black India ink. Banana peels 
were incubated in ink for ten minutes and then were washed using 10% formalin. 
Markers were stored in 10% formalin at room temperature until usage. Carrier tubes 
were filled with 5 mL warm water (45 °C), which has surrounded the small tubes and 
prohibited the solidification of gel through next steps. Tubes were centrifuged at 2000 
RPM for five minutes. Small tubes were carefully removed out of the carrier tubes 
and placed in fridge at 4 °C for one hour in order to let the gel solidify. Afterwards, 
gels were removed from the small tubes via injecting water underneath gels using a 




syringe. Gels were placed in labelled plastic cassettes, fixed in formalin overnight and 
embedded in paraffin. 
 
2.2.1.3. Immunohistochemistry (IHC) 
Immunohistochemistry was used to evaluate expression levels of FGFR1 protein and 
phosphorylation levels of Akt in lung cancer tissue samples and cell blocks. The 
technique was performed as published before (Bohnenberger et al., 2018). For 
patient tissue samples, tissue microarrays embedded in paraffin were stained, while 
paraffin embedded cell blocks were used to stain cell lines. Paraffin sections of 2 µm 
thickness were cut from paraffin blocks then incubated with EnVision Flex Target 
Retrieval Solution from Dako at high PH value for FGFR1 and pAkt staining (PH=9). 
Afterwards, sections were incubated with primary antibody (anti-FGFR1, dilution: 
1:5000, Abcam or anti-pAkt 1:100 Abcam) for 20 minutes at room temperature. A 
secondary antibody conjugated to HRP was used to the primary antibody. HRP was 
visualized by DAB substrate. Mayer’s Haematoxylin staining was used for 
contrasting. Samples were evaluated under light microscopy. Intensity of the staining 
has divided samples into three groups of zero=no expression, one = weak 
expression and two = strong expression. 
 
2.2.1.4. Florescence in situ hybridization (FISH) 
Florescence in situ hybridization or FISH was used to check for FGFR1 gene 
amplification in lung cancer patient tissues as well as in lung cancer cell lines. FISH 
staining and analysis were carried out as described before (Schildhaus et al., 2012). 
For patient tissues, samples were fixed in formalin then embedded in paraffin blocks 
then re-arranged on tissue microarray blocks. For cell lines, cell blocks were fixed in 
formalin then embedded in paraffin blocks. Paraffin blocks were cut into 3-4 µm 
thickness sections then mounted on slides. VP2000 processor system was used for 
the deparaffinization, protease treatment and washing steps of the slides. Slides are 
then denatured at 75 °C and hybridized with ZytoLight SPEC FGFR1/CEN8 probe at 
37 °C overnight. Afterwards, slides were stained with DAPI. 
Positive control cells as non-tumor lung tissue or fibroblasts had to display at least 
one signal of each color to evaluate the samples. For evaluation, at least 60 nuclei 




from the green stained FGFR1 or the orange stained centromere 8 (CEN8) were 
analyzed. The sample was evaluated as positive for amplification if the ratio between 
FGFR1 signals and CEN8 signals in one cancer cell nucleus was equal to or larger 
than two, average green signals in one nucleus were larger than or equal to six or 
10% or more of the cancer cells have shown 15 or more green signals or large 
clusters. 
 
2.2.2. Cell culture 
2.2.2.1. Cell lines 
In this study, 21 human cell lines of lung cancer from different histological groups 
were used. The properties and sources of cell lines are listed in materials section 
(chapter 2.1.3). All the cell lines were cultured using RPMI 1640, Dulbecco Modified 
Eagle Medium (DMEM) or Waymouth's MB growth media. All media included 10% 
fetal bovine serum (FBS), 1% glutamine and 1% Penicillin/Streptomycin. Cells were 
incubated at 37 °C and 5% CO2 incubators. Cells were splitted every three days and 
kept between 10% and 80% confluency. For cells detachment, 0.05% Trypsin-EDTA 
was used. 
 
2.2.2.2. Cryopreservation of cell lines 
Cells were cultured until appropriate density then detached from flasks using 0.05% 
Trypsin-EDTA (in case of adherent cells). Cells were centrifuged at 1400 RPM, re-
suspended in freezing medium (5% DMSO in FCS) and then kept for 24 hours in 
freezing boxes (Mr. Frosty) at -80 °C. Cell lines were preserved in liquid nitrogen for 
long time or in -80 °C freezer for short time preservation. 
 
2.2.2.3. Western blot 
To collect protein lysates, cells were collected, centrifuged at 1400 RPM and then 
incubated with NP-40 lysis buffer on ice for 20 minutes. Cell lysates were collected 
from the supernatant face after the second centrifugal step (at 14,000 RPM for 20 
minutes). In order to load equal amounts of cell lysates, concentrations of lysates 
were determined using DC protein assay kit and read on plate reader (TECAN 200M 
pro). Equal amounts of lysates were denatured using SDS loading buffer at 95 °C for 




five minutes. Lysates were loaded on mini-protean precast gels (4-20%). Proteins 
were separated using voltage between 70 and 120 volts. Proteins were transferred 
from gels to nitrocellulose membranes using Trans-Blot Turbo. Membranes were 
then blocked using 5% milk-TBST buffer for one hour at room temperature and 
incubated with primary antibodies either for two hours at room temperature or 
overnight at 4 °C. Membranes were washed three times for ten minutes each using 
TBST buffer then incubated with the appropriate secondary antibody for one hour at 
room temperature. Membranes were washed three times for ten minutes each. Re-
incubation with primary antibodies was feasible through five minutes incubation with 
Reblot Plus Strong antibody stripping solution at room temperature. Signals were 
developed using Western Plus-ECL and Fusion Fx, peQlab camera.  
 
2.2.2.4. MTS assay 
MTS assay is a colorimetric assay, which depends on reduction of MTS tetrazolium 
compound through the NADPH dehydrogenase enzyme in living cells. Only viable 
cells can reduce tetrazolium compound to the soluble formazan with a specific color, 
which can be detected using plate readers at absorbance between 490 and 500 nm 
(Aslantürk, 2018). For the assay, cells were seeded in 200µl cell culture medium in 
96-well plates with the appropriate density and then incubated with either an inhibitor 
or DMSO for inhibition assays or with either specific or control siRNA for proliferation 
assays. After the appropriate incubation time, 20 µL of MTS reagent (Cell titer 
aqueous one solution) were added to the cells and incubated for three hours at 37 
°C.  Intensity of formazan dye was measured on TECAN 200m Pro plate reader 
(wavelength=660 nm). Results were controlled through comparison to DMSO 
treatment, day one or control siRNA in case of inhibition assays, proliferation assays 
or siRNA knockdown, respectively. 
 
2.2.2.5. Cell counting and viability using Guava® Muse® cell analyzer 
Viable cells were counted using Guava Muse cell analyzer. Briefly, cells were 
detached using 0.05% EDTA-trypsin. Trypsin interaction was stopped using equal 
amounts of complete growth medium. Next, cells were collected in 15 mL falcon 
tubes and centrifuged for five minutes at speed of 1400 RPM.  Supernatant was 




discarded and cells were re-suspended in 3 mL growth medium. Appropriate volume 
of cell suspension (20 µL or 50 µL depending on cells concentration) was mixed with 
count and viability reagent (380 µL or 450 µL) and incubated for five minutes at room 
temperature. Viable cell number and concentration were measured using Muse cell 
analyzer. 
 
2.2.2.6. PI viability assay 
Propidium iodide (PI) stain was used to detect percentage of viable cells. Cells were 
incubated with the appropriate inhibitor or DMSO for the recommended duration. At 
the time of analysis, growth medium was removed, and cells were harvested using 
0.05% trypsin-EDTA. Cells were washed one time with PBS, moved to FACS tubes 
and then washed once again and centrifuged for five minutes at speed of 300 g. For 
each sample, 7 µL of 10 µg/mL PI stain was added and incubated for ten minutes at 
room temperature and then analyzed using BD flow cytometer.   
 
2.2.3. Cloning 
2.2.3.1. Antibiotic killing curves 
Antibiotic killing curves were used to determine the lowest concentration of the 
antibiotic, which can lead to death of cell lines. Transfection vectors had antibiotic 
resistance genes, which led to survival of successfully transfected cell lines due to 
antibiotic resistance gene on the transfected plasmid. Cell lines were incubated with 
elevated concentrations of Neomycin (G418) (100-1000 µg/mL) in normal growth 
medium for one week. The lowest concentration, which led to the complete death of 
cells after seven days was chosen as the appropriate selection concentration for this 
cell line.   
 
2.2.3.2. Expression vectors 
Protein kinase B / Akt1 was constitutively activated in different lung cancer cell lines 
using human expression vectors. pcDNA3 Myr-Akt1 (Akt vector) as well as pcDNA3 
Flag HA (control vector) plasmids were obtained from Addgene company. The pair of 
plasmids were designed with neomycin resistance genes for selection. Plasmids 
were seeded on agar plates with ampicillin (100 µg/mL) and single clones were 




picked after 18 hours. Clones were expanded in LB growth medium with ampicillin 
and then purified using plasmid maxiprep kit from Qiagen according to the 
manufacture’s protocol. 2.5 µg of Akt1 expression vector or pcDNA3 empty vector 
were complexed with 7 µg of Lipofectamin3000 transfection reagent in 500 µL serum 
free medium. Complexing mixtures were incubated for ten minutes at room 
temperature. Transfection mixtures were added drop wise to the corresponding cells 
seeded in 6-well plates. Successfully transfected cells were selected using Geneticin 
antibiotic (G418) according to cells’ antibiotic killing curves. The complete death of 
non-transfected cells was taken as a proof of successful transfection. Expression 
levels of phosphorylated Akt were evaluated using western blotting. 
 
2.2.3.3. Knockdown using siRNA 
Fibroblast growth factor receptor 1 was knocked down in different lung cancer cell 
lines using siRNA. Two functionally verified siRNAs against FGFR1 gene were 
purchased from Qiagen Ltd. The two siRNAs had catalogue numbers of SI02224684 
andSI02224677. The specific effect of FGFR1-siRNAs was controlled using a 
scrambled control siRNA from the same company (Allstars negative control siRNA 
®). All siRNAs, including FGFR1-targeted and controls, were used at a concentration 
of 30 nM and were transfected using Hiperfect transfection reagent. All starts control 
siRNA with a modification of Alexa Fluor 488 florescence color was used to control 
the transfection efficiency of siRNA in targeted cells using FACS machine. The 
general protocol of siRNA preparation included dilution of siRNA at the appropriate 
concentration using serum-free growth medium. Next, siRNAs were incubated with 
the transfection reagent Hiperfect for ten minutes at room temperature to allow 
formation of transfection lipid vesicles. Transfection mixture was added drop wise on 
top of cells then incubated in 37 °C incubator. For immunoblotting of knocked down 
cell lines, cells were seeded in 6-well plates, treated with siRNAs and then harvested 
and lysed after 48 hours. For proliferation assays, cell lines were seeded in 96-well 
plates in triplicates and then treated, incubated and measured every 24 hours for six 
days.   
 
 




2.2.3.4. CRISPR/Cas9 knockout 
In this project, CIRSPR/Cas9 was used to knockout FGFR1 gene in the SQCLC 
H1703 cell line. Two gRNAs (5’TTCCCAGGTCCCCTAAGAGG3’ & 
5’GGAGCACCAGTGTAGCCAGG3’) have been designed using Zhang lab and 
Cistrome online tools. The gRNAs were designed to target introns up and down 
stream of exon 14 in the FGFR1 gene. One of the two primers was cloned in a green 
florescence protein (GFP)-Cas9 vector backbone (no. PX458, Addgene), while the 
other primer was cloned in mCherry-Cas9 backbone (no. 64217, Addgene). Cloned 
primers were transformed into DH5alpha competent bacteria and let to grow on agar 
plates with ampicillin at 37 °C overnight. Bacterial clones were picked up and 
expanded in LB medium with ampicillin for another 18 hours then harvested and 
purified using Qiagen maxiprep. The success of cloning was verified through 
sequencing of Cas9-backbones using U6 primer 
(5’GAGGGCCTATTTCCCATGATTCC3’). Successfully cloned primers from both 
GFP and mCherry vectors were diluted in serum-free medium alongside with P3000 
transfection reagent in two different tubes. Lipofectamine3000 transfection reagent 
was diluted in serum-free medium in another tube. The two reagents and DNA were 
mixed and allowed to complex for ten minutes at room temperature to form lipid 
transfection vesicles. 
 Transfection mixture was added dropwise on the cells in 6-well plates and incubated 
at 37°C incubator. After 18 hours, growth medium was changed and successful 
double transfection was checked using ZOE fluorescent cell imager microscope. 
After 48 hours, double transfected cells were sorted into single cells on 96-well plates 
using BD FACS sorter. Three weeks after sorting, single growing clones have been 
marked on the 96-well plates. Five weeks after sorting, clones were transferred to 24-
well plates and subsequently 6-well plates. Finally, clones were tested for the 
success of knockout using western blot and DNA sequencing.     
 
2.2.3.5. DNA extraction 
For DNA extraction, Qiagen DNA extraction kit was used. DNA was extracted 
according to the manufacture’s protocol. Cells were lysed with 300 µL cell lysis 
solution with 10 µL Proteinase K and then incubated at 56 °C for 30 minutes. 
Afterwards, 1.5 µL Rnase A solution was added and incubated with lysates for 30 




minutes at 37 °C. One hundred µL protein precipitation solution was added to the 
lysates with vortex of 20 seconds. Lysates were centrifuged at 14000 RPM for three 
minutes at room temperature. Supernatant was moved in new tubes, washed with 
300 µL 100% isopropanol and then centrifuged again at 14000 RPM for three 
minutes at room temperature. Pellets were washed with 300 µL 70% ethanol and 
centrifuged for five minutes at 14000 RPM at room temperature. Supernatant was 
removed, pellets were let to dry and then re-suspended in 20-50 µL RNase free 
water. 
 
2.2.3.6. Sanger sequencing 
DNA sequencing of plasmids or cell lines was carried out according to BigDyeTM 
Terminator v3.1 sequencing kit protocol. For cell lines, an initial step included 
amplification of target DNA sequence using polymerase chain reaction (PCR) 
followed by a cleaning step using ExoSAP clean up kit. For plasmids, purified DNA of 
plasmids was used directly without additional cleaning steps. DNA sequencing 
included three main steps: PCR reaction using BigDye™ Terminator v1.1 Cycle 
Sequencing Kit, cleaning step using BigDye XTerminator™ purification kit and 
reading step performed using 3500 DX Series Genetic Analyzer from ThermoFisher 
Scientific. Results of DNA sequencing were analyzed using Geneiousprime 2019 
software. 
 
2.2.3.7. Library preparation for Archer FusionPLEX CTL sequencing panel  
An amount of 200-500 ng of DNA was extracted from cell lines. DNA was then 
sheared using a focused-ultrasonicator into fragment sizes of around 300 bp. The 
NEBNext Ultra II DNA library was used to prepare the sequencing libraries. Average 
reads developed per each sample was 17.1 million reads. The human reference 
genome (HG19) was used to map the sequences using version 0.7.12 of BWA. 
 
2.2.4. Phosphoproteomic Mass spectrometry analysis 
2.2.4.1. SILAC metabolic labeling 
Complete SILAC medium was prepared using SILAC growth medium depleted of 
arginine and lysine amino acids, 10% of dialyzed FBS which has significantly low 




concentrations of small molecules like amino acids, medium weight arginine (13C6) 
and medium weight lysine (4,4,5,5-D4) or heavy weight arginine (13C6, 15N4) and 
heavy weight lysine (13C6, 15N2), Na-pyruvate, glutamine and penicillin-
streptomycin antibiotics. To achieve high level of heavy amino acids incorporation, 
cells were incubated for at least ten cell divisions in SILAC medium at 37 °C and 5% 
CO2 incubator. Prior to lysing, medium SILAC labelled cells were treated with DMSO 
and heavy labeled cells with 0.5 µM AZD4547 for three hours. 
 
2.2.4.2. Lysing SILAC labelled cells 
SILAC labelled cells were washed once with ice-cold PBS to remove residuals of 
growth medium and to stop cellular interactions. Washing was followed by scraping 
cells on ice-cold PBS using 25 cm cell scrapper followed by centrifugation of cells 
(1300 rpm, 5 min. at room temperature). Cell pellets were divided into two groups for 
global proteome and pyome analysis with a ratio of 1:2. 
Global proteome pellets were lysed using global proteome NP40 lysis buffer 
(described in materials section: 2.1.6) for 20 minutes on ice. Cell pellets were 
centrifuged at 20,000 RPM for 20 minutes at 4 °C. Lysates were collected from 
supernatant layer and moved to Eppendorf lobind tubes. Lysates’ concentration was 
measured using Pierce™ BCA Protein Assay Kit followed by snap freezing in liquid 
nitrogen. Lysates were kept at -80 °C. 
Pyome cell pellets were lysed using urea lysis buffer (described in materials section: 
2.1.6) for 20 minutes at room temperature. Pyome lysates were then sonicated using 
15 W output with 1-2 bursts for ten seconds each. Cell pellets were then centrifuged 
at speed of 20,000 RPM for 20 minutes at room temperature. Lysates were collected 
from the upper phase into 15 mL falcon tubes. Concentration of lysates was tested 
through Pierce™ BCA Protein Assay. Pyome lysates were snap frozen using liquid 
nitrogen then held in -80 °C freezer. 
 
2.2.4.3. Mass spectrometry sample preparation  
Preparation of LC-MS/MS samples followed the previously published protocols 
(Corso et al., 2016; Mohr et al., 2017). To enrich peptides for global phosphorylation, 
equal amounts of lysates labelled with SILAC medium were mixed together then 




reduced using 10 mM DTT for 1 hour at 65 ºC and alkylated using 20 mM IAM for 1 
hour at 37 ºC. Afterwards, trypsin was used to digest the lysates. Trypsin was used at 
concentration of 1:20 to 1:50 weight/weight of trypsin: protein at 37 ºC in 0.1% 
RapiGest. Digested peptides were then acidified using 1% formic acid and 
centrifuged for 30 minutes at maximum speed. To enrich peptides for global 
phosphorylation, fractions of GPome cell lysates were applied to TiO2 columns, 
washed three times on spin columns, eluted using 0.5 M NH4OH, desalted on C18 
spin column and dried in a speed vacuum centrifuge.  
To enrich peptides for tyrosine phosphorylation, pYome cell lysates were mixed 
together in equal ratios of light, medium and heavy SILAC media labelled lysates. 
Next, PTMScan® Phospho-Tyrosine (P-Tyr-1000) Rabbit mAb Kit was used 
according to the manufacturer procedure and the previously published protocols 
(Rush et al., 2005). Briefly, tyrosine phosphorylated peptides were purified through 
their immunological affinity to tyrosine antibodies, which were conjugated to agarose 
beads then washed and  eluted with a diluted acid. Peptides were then fractionized 
using strong cation exchange (SCX) as described before (Mohr et al., 2017). 
 Next, samples were loaded on high performance liquid chromatography (HPLC) 
column using 0.1% formic acid and 80% acetonitrile with 0.1% formic acid as buffers 
A and B, respectively. HPLC system (temperature set at 50 ºC) was adjusted on a 
flow rate of 300 nL per minute. Liquid chromatography system was coupled online to 
Q ExactiveTM HF Hybrid Quadrupol-Orbitrap mass spectrometer. The data dependent 
acquisition and automatic switch between first and second scans (MS and MS/MS) 
were chosen. Precursor ions of charges between 2 and 5 were selected for the 
second MS. Raw MS data was analyzed with MaxQuant according to the published 
protocol (Cox & Mann, 2008). Andromeda search engine was used to map the 
quantified sites to Uniprot human database. False discovery rate (FDR) was set to 
1%. Perseus analysis tool was used to test quality and annotation of the quantified 
sites. 
 
2.2.4.4. Perseus phosphoproteomic data analysis 
To analyze phosphoproteomic data, I used Perseus software version number 
1.6.10.43. Data analysis followed the general scheme of work described by 




developers (Tyanova & Cox, 2018; Tyanova et al., 2016). Firstly, I filtered the sites 
for potential contaminants and reverse recognized peptides. Then, site table was 
expanded to combine multiple phosphorylated sites followed by checking normal 
distribution of data after transforming it into log2. Multi-scatter plots were used to 
calculate the R values, which show the similarities between replicates in each 
sample. Data was filtered according to localization probability > 0.75. Samples were 
renamed and grouped together followed by calculating the average of technical 
replicates. Statistical analyses were carried out using different biological replicates for 
each sample. To generate heatmaps, data were z-scored as well as compensated for 
missing values. Heatmaps were generated to compare different groups based on all 
phosphosites as well as ANOVA+ significant enriched phosphosites. Volcano plots 
were generated using student t-test to compare each sample to the control sample. 
 
2.2.4.5. Statistical analysis 
Correlations between pathological features of patients and FGFR1 gene amplification 
or protein expression were carried out using Person’s coefficient, Chi-square test and 
Contingency test. Overall survival of patients was correlated to amplification or 
expression using Kaplan-Meier analysis. P-values were calculated according to 
Mantel-Cox, Chi-square and student t tests. P-values of less than or equal 0.05 were 
considered statistically significant. Combination indexes (CI) were calculated 
according to Chou-Talalay method. CompuSyn software was used to calculate CI 
values, which identified the nature of multiple drug interaction. CI  1, CI  1, CI  1 







3.1. Studying prevalence and correlation of FGFR1 gene 
amplification and protein expression in lung cancer patients 
3.1.1. FGFR1 amplification as molecular target in squamous cell lung cancer  
Fibroblast growth factor receptor 1 (FGFR1) gene amplification is a potential 
molecular target in squamous cell lung cancer (SQCLC). In order to study the 
relevance of FGFR1 amplification as a molecular target, prevalence of FGFR1 gene 
amplification has to be established among lung cancer patients. The first aim of the 
project was to examine and validate FGFR1 gene amplification as well as protein 
expression levels among lung cancer patients. Collection of patient samples and their 
immunohistochemical diagnosis were done in collaboration with Anna-Maria Lois, 
Institute of Pathology, University Medical Center of Goettingen, Germany. Gene 
amplification diagnosis of patient samples was done in collaboration with group of 
Prof. Dr. Hans-Ulrich Schildhaus, institute of Pathology, University Medical Center of 
Goettingen, Germany. 
In order to test FGFR1 prevalence, a cohort study consisted of 421 lung cancer 
patient samples was established. The cohort included 208 patients (49.4%) 
diagnosed with squamous cell lung cancer (SQCLC), 121 patients (28.7%) 
diagnosed with pulmonary adenocarcinoma (AC) and 45 patients (29.9%) diagnosed 
with small cell lung cancer (SCLC). Males formed 70.1% of the cohort, while females 
formed 29.9% of the cohort. The median age of patients was 66 years with range of 
34 to 85 years. Tissue samples were collected through surgical resections at different 
stages of the tumor. Stages of lung cancer were classified and assigned according to 
TNM classification of the Union for International Cancer Control (UICC) edition 
number 7. Stage I formed 47.7% of the group followed by 25.9%, 19% and 1.9% for 
stages II, II and IV, respectively. The follow-up time had a median of 30 months and 
ranged between 1 and 196 months. During the follow-up time, 227 patients deceased 
while 166 were alive. General histopathological and clinical features of patients are 








Table 2: Lung cancer patient characteristics. 
 
AC: adenocarcinoma, SQCLC: squamous cell lung cancer and SCLC: small cell lung cancer. 
 
3.1.2. FGFR1 gene amplification in SQCLC and SCLC samples 
Amplification of the FGFR1 gene, located on chromosome 8, was diagnosed using 
fluorescence in situ hybridization (FISH). SQCLC as well as SCLC tissue samples 
were hybridized with green fluorescent and orange fluorescent probes against 
FGFR1 gene and centromere 8 (CEN8), respectively. Ratios of FGFR1/CEN8 
(green/red) signals were calculated. Amplification was accredited if the ratio between 
FGFR1 signals and CEN8 signals in one cancer cell nucleus was equal to or larger 
than two, average green signals in one nucleus were larger than or equal to six or 
10% or more of the cancer cells showed 15 or more green signals or large clusters 







Figure 5: FGFR1 gene amplification in tissue samples of lung cancer patients. 
FISH analysis of FGFR1 gene amplification in an amplified sample (A) and a non-amplified 
sample (B). Green signals indicated FGFR1 gene, while red signals indicated centromere 8.  
Modified from: (Elakad et al., 2020). 
 
FISH analysis showed amplification of FGFR1 gene in 37 out of 156 (23%) evaluable 
SQCLC samples. In the SCLC group, FGFR1 gene was amplified in 3 out of 37 (8%) 
evaluable samples (Figure 6).  
 
Figure 6: Prevalence of FGFR1 gene amplification in lung cancer patient tissue samples.  
FISH analysis detected prevalence of FGFR1 gene amplification in SQCLC and SCLC patient 
samples. Modified from: (Elakad et al., 2020). 
 
In order to test if FGFR1 gene amplification status can be used as a prognostic factor 





FISH analysis. Kaplan-Meier analysis did not show any significant correlation 
between the two factors in SQCLC (p=0.73, HR=0.92 and 95% CI=0.58-1.45) or 
SCLC (p=0.69HR=1.4 and 95% CI=0.26-7.51) (Figures 7A and B).  
 
Figure 7: Survival analysis according to FGFR1 amplification in lung cancer patients.  
Kaplan-Meier curves compared survival in amplified vs. non-amplified patient samples in SQCLC (A) 
and SCLC (B). P-values were calculated according to Mantel-Cox Chi-square test. Modified from: 
(Elakad et al., 2020). 
 
3.1.3. Validation of immunostaining 
Immunohistochemistry (IHC) staining is prone to false positive or negative results due 
to off-target binding. In order to validate specificity and accuracy of the anti-FGFR1 
antibody as well as the used protocol, I used two different methods.  First, I stained 
normal human tonsil and gallbladder tissue samples. Protein expression levels as 
well as RNA levels in these tissues are well established and validated. Results of IHC 
showed that tonsil tissue was a weakly positive tissue for FGFR1 expression while 
gallbladder tissue was a strong expressing tissue. These results correlated to RNA 
and protein expressions published by proteinatlas.org, FANTOM5 and HPA 






Figure 8: Validation of anti-FGFR1 antibody in human tissue samples.  
Immunohistochemistry staining of human healthy tonsil tissue (A) and gallbladder tissue (B). All 
images were captured at 40x magnification. Modified from: (Elakad et al., 2020). 
 
Secondly, I used the CRISPR/Cas9 system to knock out the FGFR1 gene in a human 
lung cancer cell line (H1703). The cell line H1703 is a SQCLC cell line, which 
normally expresses high level of FGFR1 protein. Two different guide RNAs were 
designed to target introns upstream and downstream of exon number 14 leading to 
its complete deletion. 
The targeted exon was chosen as it forms part of the vital intracellular kinase domain 
of the receptor. All 21 isoforms of FGFR1 protein include exon 14, which assured the 
disruption of all isoforms. Last characteristic of exon 14 is that it consists of 191 
nucleotides, which is not divisible by three. This feature leads to a frameshift mutation 
in the downstream sequence of the gene upon deletion (Figure 9A). Successful 
knockout of FGFR1 gene was validated using western blot (WB) staining of FGFR1 
protein in control and knockout cell line as well as DNA sequencing (Figures 9B and 
C). Park7 was used as a loading control in all western blotting experiments. The 
aforementioned protein was chosen over other conventional loading controls due to 
its high expression stability among different human tissues and cell lines (Wisniewski 







Figure 9: CRISPR/Cas9 knockout of FGFR1 gene in H1703 lung cancer cell line. 
Diagram shows strategy of FGFR1 gene knockout using two different gRNAs (A). Western blot 
staining of FGFR1 protein expression in control H1703 cell line compared to FGFR1-knockout H1703 
cell line (B). PARK7 was used as a loading control. DNA sequencing of exon 14 in H1703 control and 
knockout cell lines (C). Modified from: (Elakad et al., 2020). 
 
Immunocytochemistry (ICC) staining of the knockout H1703 cell line showed a 
complete loss of FGFR1 signal compared to control H1703, which completed the 
validation of the anti-FGFR1 antibody as well as the protocol used for 
immunostaining (Figures 10A and B). 
 
Figure 10: Validation of anti-FGFR1 antibody using the FGFR1-knockout cell line. 
Immunocytochemistry staining of FGFR1 protein in control H1703 cell line (A) and FGFR1-knockout 







3.1.4. FGFR1 protein expression in lung cancer 
FGFR1 protein expression levels were analyzed in SQCLC, AC and SCLC patient 
samples by immunohistochemistry (IHC). Expression of FGFR1 protein was 
evaluated according to a three-level scoring system; strong expression, weak 
expression and no expression (Figures 11A-C).  
 
Figure 11: IHC staining of FGFR1 protein expression in SQCLC patient tissue samples.  
Images show level of FGFR1 protein expression in negative sample (A), weak expression sample (B) 
and strong expression sample (C). All images were captured at 40x magnification. Modified from: 
(Elakad et al., 2020). 
 
FGFR1 protein was strongly expressed in 16 out of 171 (9%) evaluable SQCLC 
samples. In SCLC samples, strong expression was detected in 2 out of 44 (4%) 
evaluable samples, while in AC strong expression was detected in 40 out of 144 
(35%) evaluable samples (Figure 12). 
 
Figure 12: FGFR1 protein expression in SQCLC, SCLC and AC patient tissue samples. 
Immunohistochemistry detected strength and prevalence of FGFR1 protein expression in SQCLC, 





Next, I tested if FGFR1 protein expression can predict overall survival of patients 
through correlating patients’ survival to expression levels in the three lung cancer 
groups. Kaplan-Meier curves alongside with chi-square analysis showed correlation 
p-values of p = 0.922, p = 0.72 and p = 0.44 in SQCLC, SCLC and AC, respectively. 
Survival analysis showed that there was no significant correlation between 
expression level of FGFR1 and overall survival in any of the three tested groups 
(Figures 13A-C). 
 
Figure 13: Correlation between FGFR1 protein expression and lung cancer patients’ overall 
survival. 
Kaplan-Meier analyses showed no significant association between FGFR1 expression and survival in 
SQCLC (A), SCLC (B) and AC (C). Statistical analysis was carried out using Chi-square test. Modified 






3.1.5. Correlation between FGFR1 gene amplification and protein expression 
in lung cancer 
In order to check if FGFR1 gene amplification is constantly accompanied by protein 
overexpression, I correlated FISH to IHC data in SQCLC and SCLC groups. In 
SQCLC group, both amplification and protein expression together were evaluable in 
129 samples. Correlation showed that in the amplified SQCLC group, 35% were 
positive for protein expression, while 65% were negative. In the non-amplified 
SQCLC group, 29.6% were positive for FGFR1 expression, while 70.4% were 
negative. Chi-square test showed non-significant correlation (p=0.54) between 
FGFR1 gene amplification tested by FISH and protein expression tested by IHC 
(Figure 14A). In SCLC group, 36 samples were evaluable for both FGFR1 gene 
amplification and protein expression from the same set. Only four samples showed 
FGFR1 protein expression with no gene amplification and three SCLC samples were 
positive for FISH and negative for IHC (p=0.99) (Figure 14B). 
In the interest of expanding the correlation test between FGFR1 amplification and 
protein expression, I evaluated the correlation in 14 lung cancer cell lines. Gene 
amplification was tested through FISH analysis and protein expression was tested 
with western blot and ICC. In amplified FGFR1 cell lines, 4 out of 5 (80%) cell lines 
showed strong expression of FGFR1 protein. In non-amplified FGFR1 cell lines, three 
out of nine (33%) cell lines showed strong FGFR1 protein expression. Chi-square 
analysis showed a non-significant correlation between the two factors (p=0.09) 






Figure 14: Correlation between FGFR1 gene amplification and protein expression. 
FGFR1 gene amplification tested by FISH analysis was compared to FGFR1 protein expression tested 
by IHC in SQCLC patient tissues (A) and SCLC patient samples (B) or by ICC and western blot in lung 
cancer cell lines (C). Statistical analysis was carried out using Chi-square test. Modified from: 

















3.2. Studying mechanisms of resistance to FGFR1 inhibition in 
lung cancer 
3.2.1. Screening sensitivity to FGFR1 inhibition in human lung cancer cell 
lines 
Clinical trials of FGFR1 inhibitors have proven the concept of efficacy in FGFR1 
amplified SQCLC patients. However, moderate partial response and progression free 
survival outcomes have suggested existence of resistance mechanisms that 
originally exist in patients or develop subsequent to inhibitors exposure.(Aggarwal et 
al., 2019; Nogova et al., 2017) In order to study mechanisms of resistance to FGFR1 
inhibition, an appropriate cell line model had to be established. For this aim, I 
analyzed sensitivity to FGFR1 inhibition in 21 human lung cancer cell lines. DMS114, 
DMS53, H1339, H69, H82, HCC33, OH1, OH3, SCLC21H, SHP77 and SW2 are 
small cell lung cancer cell lines. H1703, H2170, HCC15, H520, H226, LK2, EBC1 
and SKMES1 are squamous cell lung cancer cell lines. H1581 and LCLC103H are 
large cell lung cancer cell lines. 
MTS viability assay was used to test the sensitivity to FGFR1 inhibition. Cell lines 
were incubated with increasing concentrations of AZD4547 for 72 hours. The assay 
showed that, among the 21 cell lines tested, the three cell lines H1581, LK2 and 
DMS114 had the highest sensitivity to the FGFR1 inhibitor AZD4547 with IC50 
values of 0.03M, 0.05 M and 0.06 M, respectively. On the other hand, the 
majority of cell lines (18 cell lines, 86%) showed very low sensitivity to the inhibitor 







Figure 15: Screening sensitivity of lung cancer cell lines to FGFR1 inhibition. 
Twenty-one human lung cancer cell lines were inhibited with the FGFR1 inhibitor AZD4547 at five 
increasing concentrations from 0.001 to 5 µM for 72 hours. MTS assay showed viability of cell lines 
calculated as fraction of control cells treated with DMSO. 
 
3.2.2. FGFR1 amplification in human lung cancer cell lines 
Next, I tested FGFR1 gene amplification status in 11 of the previously described cell 
lines. Selection of the 11 cell lines was based on their sensitivity to the FGFR1 
inhibitor AZD4547. FISH analysis technique was chosen to check for FGFR1 gene 
amplification in paraffin embedded cell blocks of the cell lines. Five cell lines (H1581, 
DMS114, H520, H1703 and DMS53) out of 11 cell lines tested (45.5%) had an 












Table 3: FGFR1 gene amplification analyzed by fluorescence in situ hybridization (FISH) in 
multiple lung cancer cell lines. 
 
 
3.2.3. Assigning cell line model to study FGFR1 inhibition resistance in lung 
cancer 
With the purpose of building a representative cell line model, I included three groups 
of cell lines: a sensitive group, a resistant group and a control group. In the sensitive 
group, I chose the three cell lines H1581, LK2 and DMS114. H1581 and DMS114 cell 
lines showed FGFR1 gene amplification and high sensitivity to FGFR1 inhibition. LK2 
showed no amplification of the FGFR1 gene but high sensitivity to FGFR1 inhibition. 
In the non-sensitive or resistant group, I chose the two cell lines H520 and H1703 
with high FGFR1 amplification and expression level and low sensitivity to FGFR1 
inhibition. In the control group, I chose HCC15 and H2170 cell lines with normal 
FGFR1 gene copy number and no sensitivity to FGFR1 inhibition (Figure 16). 
DMS53 cell line showed amplification of FGFR1 gene with no sensitivity to FGFR1 
inhibition. However, DMS53 cell line showed minimal expression of FGFR1 protein, 






Figure 16: Prevalence of FGFR1 gene amplification (FISH analysis) in lung cancer cell lines. 
FGFR1 gene amplification was detected by FISH analysis in control (A and D), resistant (B and E) and 
sensitive (C, F and G) cell lines to FGFR1 inhibition. 
 
3.2.4. FGFR1 protein expression in human lung cancer cell lines 
Next, I tested FGFR1 protein expression levels in the seven cell lines in my model. 
Protein expression levels were tested using western blotting (WB) and 
immunocytochemistry (ICC) using paraffin embedded cell blocks of the cell lines. 
Western blotting and ICC showed that FGFR1 protein was strongly expressed in five 





H520 and H1703 cell lines). On the other hand, control group cell lines (HCC15 and 
H2170 cell lines) showed no FGFR1 protein expression (Figures 17 and 18). 
 
 
Figure 17. FGFR1 protein expression in multiple lung cancer cell lines.  
Western blot showed FGFR1 expression in the seven lung cancer cell lines formed the model. PARK7 







Figure 18: Immunocytochemical staining of FGFR1 protein in lung cancer cell lines.  
ICC images showed levels of FGFR1 expression in control (A and D), resistant (B and E) and 
sensitive (C, F and G) cell lines to FGFR1 inhibition. All images were captured at 40X magnification.  
 
Collectively, my model consisted of three groups: a sensitive/responder group, a 
resistant group and a control group. The sensitive group included H1581 and 
DMS114 cell lines with FGFR1 gene amplification and strong protein expression and 
LK2 cell line with no FGFR1 gene amplification but with strong protein expression. 
The resistant group included H520 and H1703 cell lines with FGFR1 gene 
amplification and strong protein expression. Finally, the control group included 
HCC15 and H2170 cell lines with no FGFR1 gene amplification and negative protein 






Figure 19: Collective status of FGFR1 gene amplification and protein expression in lung cancer 
cell lines.  
Western blot showed expression of FGFR1 protein in 14 lung cancer cell lines. FGFR1 amplification 
was measured by FISH analysis. Sensitivity to the FGFR1 inhibitor AZD4547 was measured by MTS 
viability assay. FGFR1 protein expression was measured by western blot and immunocytochemistry. 
PARK7 was used as a loading control.  
 
3.2.5. Validation of sensitivity to FGFR1 inhibition in the cell line model 
The first step of validating sensitivity of the model to FGFR1 inhibition was done 
through MTS viability assay. The seven cell lines were incubated with increasing 
concentrations of AZD4547 (FGFR1 inhibitor) for 96 hours. The assay was repeated 
with three biological replicates and three technical replicates. MTS viability assay 
confirmed previous sensitivity pattern of the model where H1581, LK2 and DMS114 
cell lines had IC50s  0.1 M, while H520, H1703, HCC15 and H2170 cell lines had 






Figure 20: Sensitivity to the FGFR1 inhibitor AZD4547.  
Sensitivity was measured via MTS viability assay after 96 hours incubation. Viability was calculated as 
fraction of control cells treated with the same concentration of DMSO. Nine increasing concentrations 
of AZD4547 were used (0, 0.003, 0.01, 0.03, 0.1, 0.27, 0.8, 2.4 and 7.3 M). Experiments were 
conducted in triplicates.  
 
Next, I confirmed the previously detected response pattern of the cell lines through 
incubation with the FGFR1 inhibitor BGJ398 for 96 hours. H1581, DMS114 and LK2 
cell lines showed IC50 values of 0.08, 0.8 and 1.2, respectively. H520, H1703, 
HCC15 and H2170 cell lines showed IC50 values higher than 5 M (Figure 21).  
 
 
Figure 21: Sensitivity to the FGFR1 inhibitor BGJ398.  
Sensitivity to the FGFR1 inhibitor BGJ398 measured through MTS assay after 96 hours incubation. 
Viability was calculated as fraction of control cells treated with the same concentration of DMSO. Nine 
concentrations of BGJ398 were used (0, 0.003, 0.01, 0.03, 0.1, 0.27, 0.8, 2.4 and 7.3 M). 
Experiments were conducted in triplicates.  
 
Further validation of response to FGFR1 inhibition was achieved through counting 
number of viable cells (via Muse flow cytometry) after incubation with the FGFR1 
inhibitor AZD4547 for 96 hours. Cell growth was evaluated as percentage of cells 
grown under inhibition compared to cells grown under vehicle (DMSO). The cell line 





compared to control. DMS114 and LK2 cell lines represented the second and third 
sensitive cell lines with growth percentages of 32% and 40%, respectively. H520, 
H1703, HCC15 and H2170 cell lines showed non-significant reduction in growth 
compared to controls (Figure 22).  
 
Figure 22: Cell growth assay (number of viable cells) after treatment with AZD4547.  
Cell lines were incubated with 0.5 µM of the FGFR1 inhibitor AZD4547 for 96 hours. Absolute 
numbers of viable cells were counted using Muse cell analyzer. Experiments were conducted in 
triplicates. P values were denoted as ns = p>0.05 and *** = p≤0.001. 
 
3.2.6. Testing AZD4547 (FGFR1 inhibitor) phosphorylation inhibition function  
AZD4547 is a specific tyrosine kinase inhibitor, which suppresses 
activation/phosphorylation of FGFR1 at its tyrosine residues through ATP 
competition. To test the efficiency of AZD4547 in inhibiting FGFR1 phosphorylation, I 
incubated cell lines with 0,5 M AZD4547 for 3 hours. Immunoblotting showed a 
significant decline in phospho-FGFR1 signals at Y654 site upon incubation with the 
inhibitor compared to incubation with DMSO in H1703, H520, DMS114, H1581 and 
LK2 cell lines. HCC15 and H2170 control cell lines lacked original phosphorylation 
signal of FGFR1 under control conditions due to minimal expression of FGFR1 






Figure 23: Phosphorylation inhibition through AZD4547.  
Western blot showed activity of AZD4547 in blocking phosphorylation at FGFR1 receptor. Cell lines 
were incubated with 0.5 µM of AZD4547 for 3 hours. PARK7 was used as a loading control.  
 
3.2.7. Testing AZD4547 (FGFR1 inhibitor) specificity using siRNA 
To exclude off-target inhibition as a reason for response to FGFR1 inhibition, I 
knocked    down FGFR1 gene via small interfering RNA (siRNA). Two different 
sequences of siRNA, which were validated by the manufacturer, were used to knock 
down FGFR1 in the seven cell lines. A scrambled siRNA, that does not target any 
sequence in human genome, was used as a control (Figure 24).  
The first step in knocking down the FGFR1 gene was to test transfection efficiency of 
the transfection reagent (HiPerFect) and siRNAs in the described cell lines. Cell lines 
were incubated for 24 hours with a control siRNA coupled with a fluorescent dye. 
Control cells were incubated only with the transfection reagent. Percentages of 
fluorescent cells were detected using FACS cell analyzer. Transfection efficiency was 
higher than 90% in all cell lines except H2170 cell line with an efficiency of 82%. 






Figure 24: Transfection efficiency of siRNAs in lung cancer cell lines.  
Transfection efficiency of siRNA was measured through FACS analyzer after 24 hours incubation with 
control siRNAs coupled with a fluorescent dye (Alexa Fluor 488). Viability of cell lines was measured 
through Propidium iodide staining. 
 
Next, I transfected cell lines with 30 nM of siRNA targeting FGFR1 and tested the 
efficiency of FGFR1 knockdown after 48 hours. H1581, DMS114, H520 and H1703 
cell lines showed strong reduction in FGFR1 expression, LK2 cell line showed 
intermediate reduction and the control cell lines HCC15 and H2170 lacked original 
expression of FGFR1 under control conditions (Figure 25).  
 
Figure 25: siRNA knockdown of FGFR1 protein.  







Finally, to test dependency of the seven cell lines on FGFR1 signaling, cell lines were 
incubated with 30 nM of either siRNA targeting FGFR1 or scrambled siRNA for six 
days. Proliferation of cell lines was measured every 24 hours through MTS viability 
assay. Proliferation was calculated as fraction of control at 24 hours incubation. The 
experiment was repeated with four biological replicates. HCC15, H2170, H520 and 
H1703 cell lines showed similar proliferation patterns between FGFR1-siRNA and 
control-siRNA groups without significant difference. H1581, LK2 and DMS114 cell 
lines showed reduction in proliferation upon incubation with FGFR1-siRNA compared 
to control-siRNA. Reduction in proliferation reached significance on the fifth day in 








Figure 26: Proliferation assay under FGFR1-siRNA knockdown.  
Cell lines were incubated with 30 nM of FGFR1-siRNAs for 6 days. Viability was measured every 24 
hours using MTS viability assay. Experiments were conducted in quadruplicates. P values were 
denoted as ns = p>0.05 and * = p≤0.05. 
 
3.2.8. Exploring activated FGFR1 signaling in the cell lines model 
In order to study mechanisms of resistance to FGFR1 inhibition, I compared activated 
signaling pathways between the three groups of cell lines (control, resistant and 
sensitive groups). The seven cell lines in my model were incubated with either DMSO 
or the FGFR1 inhibitor AZD4547 at concentration of 0.5 M for 3 hours. Proteins 
were blotted on membranes and incubated with antibodies against the main effectors 
in FGFR1 signaling. 
 
Figure 27: Western blot analysis of FGFR1 signaling in control, resistant and sensitive cell 
lines to FGFR1 inhibition.  
Cell lines were incubated with either DMSO or the FGFR1 inhibitor AZD4547 for three hours. PARK7 





Western blot analysis showed reduction in phosphorylated MEK (pMEK) signal in 
H1703 resistant cell line and DMS114, H1581 and LK2 sensitive cell lines upon 
inhibition by AZD4547. The control unphosphorylated MEK signal was unchanged. 
Activated ERK (pERK) signal was reduced in H520, H1703, DMS114, H1581 and 
LK2 cell lines upon inhibition by AZD4547 compared to DMSO. 
Phosphorylated Akt signal, particularly at the serine residue (Ser473), represented 
the major difference in signaling between the three groups (control, resistant and 
sensitive). The resistant cell lines H520 and H1703 showed highly activated Akt 
signals (Ser473 and Thr308) compared to the sensitive cell lines or the control cell 
line. Phosphorylated signals were reduced upon incubation with AZD4547. Basal Akt 
signal was unaltered between control and inhibition conditions of each cell line or 
between the three groups of cell lines. Activated PI3K signal was comparable 
between the two conditions in each cell line and between the three groups of cell 
lines. Stat3 was not activated in any of the cell lines except of H1703. PARK7 was 
used as a loading control (Figure 27).  
In order to expand the comparison between protein expression levels in the model, I 
used Archer Fusion directed thyroid and lung cancer next generation sequencing 
(CTL) panel. The panel enabled me to detect RNA levels among the different cell 
lines (Figure 28). RNA sequencing heat map showed high elevation of FGFR1 
expression in the resistant cells (H520 and H1703) as well as in the sensitive cells 
(DMS114, H1581 and LK2). FGFR1 levels were very low in the control cells (HCC15 
and H2170) compared to other cell lines. The panel showed elevation of Akt1 signal 
in H520 cell line, while only slight elevation of the same signal was detected in H1703 
cell line compared to other cell lines. No other significant differences were shown 







Figure 28: RNA-sequencing using Archer FusionPlex CTL Panel. 
Next generation sequencing directed panel compared RNA expression levels among different control, 
resistant and sensitive cell lines.  
 
3.2.9. Activation of Akt in FGFR1-amplified SQCLC tissue samples 
Western blot analysis showed that overactivation of Akt was a major distinction 
between FGFR1 signaling in FGFR1 inhibition resistant and sensitive cell lines. 
Therefore, I tested if variation of Akt activation takes place in human FGFR1-
amplified and FGFR1-expressing SQCLC patient samples. I stained 32 FGFR1-
amplified and 45 FGFR1-expressing SQCLC patient samples against phosphorylated 
Akt using IHC. Staining was analyzed under microscope and phosphorylation levels 





expression in lung cancer patient tissues was done in collaboration with Sha Yao at 
the institute of Pathology, University Medical Center of Goettingen, Germany.  
In FGFR1-amplified samples, 4 out of 32 samples (12.5%) lacked Akt 
phosphorylation completely. Intermediate/weak phosphorylation was measured in 22 
out of 32 samples (68.7%), while strong phosphorylation of Akt (H-score  240) was 
detected in 6 out of 32 FGFR1-amplified samples (18.8%). In FGFR1-expressing 
samples, 15.5%, 55.6% and 28.9% showed negative, weak and strong Akt activation 
signals, respectively (Figures 29-30). 
 
Figure 29: Immunohistochemical staining of pAkt in patient samples.  
Images show examples of negative (A), Weak (B) and strong (C) phosphorylation of Akt in FGFR1-
amplified SQCLC patient samples. All images were captured at 40-x magnification. 
 
 
Figure 30: Expression levels of phosphorylated Akt in FGFR1-amplified and FGFR1-expressing 





Strength of activated Akt signals was scored on a scale from zero to 300 in 32 FGFR1-amplified and 
45 FGFR1-expressing SQCLC patient samples. Samples with zero H-score showed complete 
absence of Akt phosphorylation while samples with 300 H-score showed the strongest. 
 
Next, I correlated the overall survival of 32 FGFR1-amplified and 45 FGFR1-
expressing SQCLC patients to their Akt phosphorylation levels. An H-score of > 240 
was used as a cut-off value for strong Akt phosphorylation. Kaplan-Meier survival 
curves showed an association between increased Akt activation levels and 
decreased overall survival in both groups. However, the correlation did not reach 
statistical significance (p values = 0.11 and 0.36 in FGFR1 amplified and expressing 
samples, respectively) (Figure 31). 
 
Figure 31: Survival analysis of FGFR1-amplified and FGFR1-expressing SQCLC patient 
samples.  
Correlation between Akt phosphorylation and overall survival of patients analyzed through Kaplan-
Meier curves.  
 
3.2.10. Combination of FGFR1 and Akt inhibition 
Next, I tested if Akt activation in H520 and H1703 cell lines was connected to their 
FGFR1 inhibition resistance.  With this aim, I inhibited Akt in the seven cell lines in 
my model. Cell lines were incubated with either the FGFR1 inhibitor AZD4547, the 
Akt inhibitor AZD5363 or both inhibitors together. The two inhibitors were used in a 
series of nine increasing concentrations. Inhibitors’ concentrations ranged between 0 
- 7.3 M and 0 - 30M for the FGFR1 inhibitor AZD4547 and the Akt inhibitor 





analyzed using MTS viability assay. Within the control cell lines HCC15 and H2170, 
combination inhibition of FGFR1 and Akt showed no distinction in viability compared 
to Akt inhibition alone. On the other hand, within the two resistant cell lines H520 and 
H1703, combination inhibition significantly reduced viability compared to either one of 
the inhibitors alone. In the three sensitive cell lines combination inhibition reduced 
viability compared to single inhibitors but to a limited level compared to resistant cell 
lines. (Figure 32). 
 
Figure 32: Combination inhibition of FGFR1 and Akt in sensitive and insensitive cell lines 
FGFR1 inhibition.  
Cell lines were treated with nine increasing concentrations of FGFR1 and Akt or both together. The 
FGFR1 inhibitor AZD4547 was used in concentrations of 0, 0.003, 0.01, 0.03, 0.1, 0.27, 0.8, 2.4 and 





30 M. Viability was measured using MTS assay after 96 hours of incubation. All experiments were 
repeated with three biological and three technical replicates.  
To investigate the nature of multiple drug interactions, I calculated the combination 
index value (CI) according to Chou-Talalay method (CompuSyn software). The 
method uses the median-effect equation to detect the nature of interactions between 
two drugs where CI  1, CI  1, CI  1 indicate synergistic, additive and antagonistic 
effects, respectively (Table 4 and Figure 33). Combination indexes showed that 
combining FGFR1 and Akt inhibition was effective and induced synergism in the two 
resistant cell lines H1520 and H1703.  










Figure 33: Synergistic effect of FGFR1 and Akt co-inhibition in H520 and H1703 cell lines.  
H520 (A) and H1703 (B) resistant cell lines were treated with both the FGFR1 inhibitor AZD4547 and 
the Akt inhibitor AZD5363 at different concentrations. Fractions of dead cells (Fa) were measured by 
MTS assay. Combination indexes (CI) were calculated using CompuSyn software based on Chou-
Talalay drug interaction algorithm. CI < 1 for synergistic effect, CI = 1 for additive effect and CI > 1 for 
antagonistic effect. 
 
3.2.11. Inducing Akt expression and activation in the sensitive cell lines 
Previous results showed that Akt activation might cause resistance to FGFR1 
inhibition. I tested this hypothesis through inducing overexpression of activated Akt in 
the three sensitive cell lines H1581, LK2 and DMS114. Therefore, I transfected the 
three cell lines with either mammalian expression vector expressing myristoylated 
Akt1 (pcDNA3-Myr-Akt1) or the same vector without myristoylated Akt1 as a control 
(pcDNA3). Myristoylation is a lipid modification, which has shown to help membrane 
localization of Akt and cause its activation (Adam et al., 2007; S. Kim et al., 2001). 
Successfully transfected cell lines were selected using Geneticin (G418), which was 
expressed by both vectors. The appropriate concentration of G418 was detected 
through G418 kill curve for each cell line. Lysates from the three sensitive cell lines 
were stained for pAkt (Ser473) and analyzed through western blot. Immunostaining 
confirmed overactivation of Akt in the Myr-Akt1 transfected cell lines compared to 
either vehicle-vector or control cells (without transfection) (Figure 34). Overactivation 
of Akt was strong in LK2 and H1581 cell lines while DMS114 cell line showed 
minimal overactivation. 
 
Figure 34: Immunoblotting of phosphorylated Akt in control and constitutively active-Akt cell 
lines.  
Activated Akt levels were measured using western blot in control cells, empty vector-transfected cell 






The effect of Akt overactivation in the three sensitive cell lines was evaluated through 
MTS viability assay. In the cell line H1581, induction of pAkt significantly reduced its 
sensitivity to the FGFR1 inhibitor AZD4547 compared to cells transfected with vehicle 
vector. In LK2 cell line, induction of pAkt also reduced the sensitivity to FGFR1 
inhibition albeit to a lesser extent. In DMS114 cell line, there was no change in 
sensitivity between pAkt-induced cells and control cells (Figure 35). 
 
Figure 35. Sensitivity to FGFR1 inhibition in mutationally activated Akt cell lines.  
Control cells (transfected with an empty vector) and pAkt overexpressing cells (transfected with pAkt-
expressing vector) were treated with the FGFR1 inhibitor AZD4547 for 96 hours. The FGFR1 inhibitor 
AZD4547 was used in concentrations of 0, 0.003, 0.01, 0.03, 0.1, 0.27, 0.8, 2.4 and 7.3 M Viability of 
the cells were measured using MTS viability assay. Experiments were conducted in triplicates.  
 
Combination inhibition of FGFR1 and Akt showed successful rescue of sensitivity to 
FGFR1 inhibition in the cell lines H1581 and LK2. No change in sensitivity to FGFR1 
inhibition was detected between Myr-Akt1 and empty vector transfected cells in 
DMS114 cell line (Figures 36). Combination indexes, calculated through Chou-
Talalay method, showed synergistic effect between the two inhibitors, which elevated 






Figure 36: Combination inhibition of FGFR1 and Akt in control and MyrAkt1 expressing cell 
lines.  
Cell lines were treated with nine increasing concentrations of FGFR1 and Akt or both together. The 
FGFR1 inhibitor AZD4547 was used in concentrations of 0, 0.003, 0.01, 0.03, 0.1, 0.27, 0.8, 2.4 and 
7.3 M. The Akt inhibitor AZD5363 was used in concentrations of 0, 0.5, 1, 5, 10, 15, 20, 25 and 30 








Figure 37: Combination index values in control and mutationally activated Akt cell lines.  
H1581, LK2 and DMS114 cell lines, which express mutant Myr-Akt1, were treated with both the 
FGFR1 inhibitor AZD4547 and the Akt inhibitor AZD5363 at different concentrations. Fractions of dead 
cells (Fa) were measured by MTS assay. Combination indexes (CI) were calculated using CompuSyn 
software based on Chou-Talalay drug interaction algorithm. CI < 1 for synergistic effect, CI = 1 for 








3.2.12. Inducing resistance to FGFR1 inhibition in sensitive cell lines 
Exposure to molecular targeted inhibitors can induce resistance to these inhibitors in 
cancer patients. In order to study mechanisms of acquired resistance, I induced 
FGFR1 inhibition resistance in the three sensitive cell lines H1581, LK2 and 
DMS114. Resistance induction was possible through incubating the three cell lines 
with high concentration of the FGFR1 inhibitor AZD4547 (5 M) over a long period. 
During resistance induction, cells were treated with several cycles of either fresh 
medium only or medium with inhibitor for three days. The level of sensitivity of the 
cells was assayed via MTS viability assay. High level of resistance was achieved 
after a period of four months (Figure 38). 
 
 
Figure 38: Acquired resistance to FGFR1 inhibition in the three sensitive cell lines.  
MTS viability assay compared sensitivity of parental cell lines and their resistant counterparts to the 
FGFR1 inhibitor AZD4547. Cells were incubated with the FGFR1 inhibitor for 96 hours. Experiments 
were conducted in triplicates. 
 
Altered signaling in the resistant cell lines was tested through western blot and 
compared to signaling in control cell lines. Repeated detection of signaling in the 
resistant cell lines showed a switch between activated and deactivated pathways 
within the same resistant cell line. Western blot was repeated at least three times for 
each cell line over a period of one month and the unstable behavior of cell signaling 
was detected repeatedly. Activated Akt was one of the effectors, which were elevated 
at certain time point and reduced afterwards in the same resistant cell line compared 
to control cells.  One explanation of the unstable signaling is the multiclonal behavior 
of the resistant cell lines where each clone developed its own resistant mechanism 






Figure 39: Western blot analysis of Akt phosphorylation levels in acquired resistant cell lines. 
Levels of pAkt were measured in the three parental cell lines DMS114, H1581 and LK2 and their 
acquired resistant counterparts in two different biological replicates. Replicates were measured two 
weeks apart. PARK7 was used as a loading control. 
 
3.2.13. Inducing resistance to FGFR1 inhibition in single clones of sensitive 
cell lines 
To test the hypothesis of multiclonal resistance mechanisms and to study 
mechanisms of resistance to FGFR1 inhibition in lung cancer, I sorted the sensitive 
cell lines into single clones. The three sensitive parental cell lines H1581, LK2 and 
DMS114 were sorted into single cells using FACS sorter on 96-well plates. Single 
cells were incubated with normal growth medium until the cells were stabilized and 
slightly expanded. Afterwards, Clones were incubated with several cycles of either 
fresh medium or medium with 5 M of the FGFR1 inhibitor AZD4547 to induce the 
resistance.  
Cycles of FGFR1 inhibition lasted for five days while cycles of recovery with fresh 
medium lasted for 20 days. Unlike batch cell lines, single clones were very sensitive 
to any medium change as well as FGFR1 inhibition. Sensitivity of the single clones 
had elongated the duration of each recovery cycle from 3 days in batch cell lines to 
20 days in single clones. The process of inducing resistance in single clones lasted 
for ten months. Resistance to the FGFR1 inhibitor AZD4547 was detected through 
MTS viability assay compared to parental cell lines. 
In H1581 cell line, I sorted 480 single cells from eight 96-well plates, in which 150 





14 (9.3) clones developed resistance to FGFR1 inhibition. In DMS114 cell line, 420 
single cells were sorted on seven 96-well plates, in which 178 clones (42.3%) 
survived. Seventeen single clones (9.6% of total single clones) developed resistance 
to the FGFR1 inhibitor AZD4547. In LK2 cell line, 540 cells were sorted on nine 96-
well plates, in which 74 (13.7%) cells survived. Percentage of developing resistance 
to FGFR1 inhibition was 22.9% (17 out of 74 single clones) in LK2 cell line (Table 5).  
Next, I investigated the altered signaling pathways in the resistant clones compared 
to their sensitive parental cell lines through western blot. In this regard, I checked and 
compared expression levels of FGFR1, phosphorylated Akt, basal Akt, 
phosphorylated ERK and basal ERK proteins. PARK7 was used as a loading control.  
Western blot showed overexpression of FGFR1 protein expression in 5 out of 14 
(35.7%), 9 out of 17 (52.9%) and 6 out of 17 (35.3%) resistant single clones of 
H1581, DMS114 and LK2 cell lines, respectively. Overactivation of Akt was detected 
in 3 out of 14 (21.4%), 5 out of 17 (29.4%) and 1 out of 17 (5.9%) resistant single 
clones of H1581, DMS114 and LK2 cell lines, respectively. Expression of 
phosphorylated ERK was elevated in 2 out of 14 (14.3%), 1 out of 17 (5.9%) and 4 
out of 17 (25.5%) resistant single clones of H1581, DMS114 and LK2 cell lines, 
respectively (Table 5 and Figure 40). 








Figure 40: Western blot analysis showing altered signaling in FGFR1 inhibition resistant clones 
compared to parental controls.  
Levels of FGFR1, pAkt, Akt, pERK and ERK were tested in single cell resistant clones of H1581 (A), 
LK2 (B) and DMS114 (C) cell lines and compared to their parental controls (Cont.). PARK7 was used 
as a loading control. 
 
3.2.14. Combination inhibition of FGFR1 and Akt in resistant single clones 
In order to investigate mechanisms of resistance to FGFR1 inhibition in depth, I 
focused my efforts on studying overactivated Akt as a mechanism of resistance. With 
this aim, I selected the three resistant clones numbered as 4, 9 and 11 of the H1581 





H1581-11R showed elevation of pAkt as one mechanism of resistance to the FGFR1 
inhibitor AZD4547.       
In order to test the dependency of the resistant clones H1581-4R, H1581-9R and 
H1581-11R on Akt signaling, I inhibited Akt alongside with FGFR1 in these clones. 
Firstly, I incubated the resistant clone H1581-11R with nine increasing concentrations 
of either FGFR1 inhibitor AZD4547 alone, Akt inhibitor AZD5363 alone or both 
inhibitors together for 96 hours. The nine different concentrations allowed me to find 
the effective concentration of the two inhibitors as well as measuring the combination 
index among different combinations. Comparison between viability of H1581-11R and 
parental cell line confirmed the resistance to FGFR1 inhibition, while response to Akt 
inhibition was not altered. Combination inhibition in H1581-11R and parental H1581 
cell line showed significant reduction in viability in the resistant clone compared to 
parental cells. Chou-Talalay equations showed synergistic effect of the combination 
inhibition in five different combination concentrations (Figures 41 and 42).  
 
Figure 41: Synergistic effect of FGFR1 and Akt co-inhibition in the FGFR1 inhibition resistant 
clone H1581-11R.   
Resistant clone number 11 of H1581 cell line was incubated with either the FGFR1 inhibitor AZD4547 
alone, the Akt inhibitor AZD5363 alone or both inhibitors together. Inhibitors were used in nine 
increasing concentrations. The FGFR1 inhibitor AZD4547 was used in concentrations of 0, 0.003, 
0.01, 0.03, 0.1, 0.27, 0.8, 2.4 and 7.3 M. The Akt inhibitor AZD5363 was used in concentrations of 0, 
0.5, 1, 5, 10, 15, 20, 20, 25 and 30 M. MTS viability assay was measured after 96 hours incubation. 







Figure 42: Combination index values indicated type of interaction between the FGFR1 inhibitor 
AZD4547 and the Akt inhibitor AZD5363 in H1581-11R resistant clone.  
The effect of combination inhibition was evaluated through MTS viability assay after 96 hours 
incubation. H1581-11R resistant clone was treated with both the FGFR1 inhibitor AZD4547 and the 
Akt inhibitor AZD5363 at different concentrations (A). Fractions of dead cells (Fa) were measured by 
MTS assay (B). Combination indexes (CI) were calculated using CompuSyn software based on Chou-
Talalay drug interaction algorithm. CI < 1 for synergistic effect, CI = 1 for additive effect and CI > 1 for 
antagonistic effect. 
 
In order to test the effect of combination inhibition of FGFR1 and Akt in the two 
resistant clones H1581-4R and H1581-9R, I incubated these clones with either 
inhibitors or combination of them for 96 hours. The FGFR1 inhibitor AZD4547 was 
used at concentration of 7.3µM while the Akt inhibitor AZD5363 was used at 
concentration of 30 µM. MTS viability assay alongside with viable cell count using 
Muse cell analyzer showed resistance of the three clones to the FGFR1 inhibitor 
(AZD4547) compared to parental H1581 cell line (Figure 43). Combination inhibition 
showed synergistic effect of combining the FGFR1 inhibitor AZD4547 and the Akt 







Figure 43: Effect of FGFR1 inhibition in parental and resistant clones of H1581 cell line.  
MTS viability assay compared viability of parental H1581 cell line and the resistant single clones upon 
treatment with the FGFFR1 inhibitor AZD4547. The assay was measured after 96 hours incubation. 
The AZD4547 inhibitor was used at concentration of 7.3 M. Experiments were conducted in 




Figure 44: Synergistic effect of FGFR1 TKI combined with Akt inhibitor in resistant clones.  
The parental H1581 cell line and the three resistant clones H1581-4R, H1581-9R and H1581-11R 
were treated with either the FGFR1 inhibitor AZD4547 alone, the Akt inhibitor AZD5363 alone or both 
inhibitors together. The AZD4547 inhibitor was used at concentration of 7.3 M. The AZD5363 
inhibitor was used at concentration of 30 M. MTS assay was measured after 96 hours incubation. 
Experiments were conducted in triplicates. P values were denoted as ns = p>0.05, * = p ≤0.05, ** = p 
≤0.01, *** = p ≤0.001 and **** = p ≤ 0.0001. 
In order to understand mechanism of resistance in the single clones more, I blotted 





incubation with either DMSO as a control or 0.5 µM AZD4547 for 3 hours on 
membranes and stained them against the main effectors in FGFR1 signaling (Figure 
45). Western blotting showed strong activation of Akt in the three resistant clones. 
The downstream Akt proteins, PRAS40 and FOXO1/3, were strongly activated in the 
three clones as well. PTEN expression was down regulated in clones C9 and C11. 
Decline of ERK and MEK activation was noticed in at least two of the resistant clones 




Figure 45: Activated signaling pathway in induced resistance single clones of H1581 cell line 
Western blot showed regulation of FGFR1 signaling pathway in the parental H1581 cell line compared 
to the three induced resistance single clones C4, 9 and 11. Cells were incubated with either DMSO or 
0.5 µM AZD4547 for 3 hours and then lysed. 
RNA sequencing using CTL directed panel showed increase in FGFR1 RNA 





three resistant clones and the parental control cell line (Figure 46).  EGFR, ERBB2, 
Akt1, BRAF, MET, KRAS and PIK3CA RNA expression were not altered between the 
resistant clones and the control.  
 
Figure 46: RNA sequencing showed protein expression levels among resistant clones. 
Archer thyroid and lung cancer directed panel was used to compare protein expression levels among 








3.3. Phosphoproteomic analysis of FGFR1 inhibition resistance in 
lung cancer cell lines 
3.3.1. Sample preparation for phosphoproteomic analysis 
In order to investigate the mechanism of resistance to FGFR1 inhibition in depth, with 
special focus on the role of Akt in FGFR1 resistance, I conducted a 
phosphoproteomic analysis using mass spectrometry. The experiment was designed 
to investigate mechanisms of resistance to FGFR1 inhibition in three different 
resistant groups and one sensitive control group. The first resistant group included 
the intrinsic resistant cell line H520. The second resistant group included the H1581 
cell line with mutationally activated Akt (H1581-mutAkt). The last resistant group 
included the two induced resistance single clones with elevated Akt activation H1581-
9R and H1581-11R. The sensitive control group included the parental H1581 cell 
line. To expand my understanding of the resistance mechanisms, I compared all cell 
lines under two different conditions. The first condition was treatment with 0.5 M of 
the FGFR1 inhibitor AZD4547 and the second condition was treatment with the same 
amount of DMSO. 
To ensure accurate measurement and comparison of proteins from different sources 
on mass spectrometry, samples had to be mixed in the same ratios and measured 
together. In order to mix samples together, I labelled the samples with SILAC 
metabolic labelling. AZD4547-treated cells were labelled with heavy SILAC amino 
acids (Lysine +8 and Arginine +10), while DMSO-treated cells were labelled with 
medium SILAC amino acids (Lysine +4 and Arginine +6). 
To compare cell lines from different groups, I spiked a standard control in each of the 
samples. The standard control consisted of equal amounts of protein lysates from the 
untreated DMS114, H1581, H1703 and H520 lung cancer cell lines. Taken together, 
each measurement group consisted of AZD4547-treated cells labelled with heavy 
SILAC, DMSO-treated cells labelled with medium SILAC and untreated light standard 








Figure 47: Design of SILAC metabolic labeling of cell lines.  
Cell lines were divided into three groups: protein quantification standard cultured in light growth 
medium, DMSO-treated group cultured in medium SILAC growth medium and AZD4547-treated group 
cultured in heavy SILAC growth medium.  
 
To ensure complete incorporation of heavy amino acids in treated cells, cell lines 
were incubated with either heavy or medium SILAC growth medium for at least ten 
cell divisions. Next, cells were harvested at confluency of 70-80%. Cell pellets were 
divided into two groups as following: one group for global proteome (GPome) and the 
second group for tyrosine phosphopeptides enrichment (pYome). Global proteome 
cell pellets were lysed with NP-40 lysis buffer, while pYome cell pellets were lysed 
with urea lysis buffer. All samples were collected for two biological replicates of each 
experiment. Enrichment of the low-abundant phosphopeptides required starting with 
large amounts of protein lysates. I collected a total of 250 mg of the light standard cell 
lysates, 195 mg of the medium SILAC labeled cell lysates and 195 mg of the heavy 
SILAC labeled cell lysates (Figure 48). 
 
 





Protein lysates were divided into two groups; the first group was for global proteome phosphorylated 
proteins and the second groups was enriched for tyrosine phosphorylated proteins. 
 
3.3.2. Phosphoproteomic LC-MS/MS data quality control 
Phosphopeptides-enrichment and fractionation was done in collaboration with group 
of Prof. Dr. Thomas Oellerich at department of Hematology and Oncology, University 
Hospital of Frankfurt, Germany. Peptides sequencing was done in collaboration with 
the group of Prof. Dr. Henning Urlaub at Max Planck institute for biophysical 
chemistry, Goettingen, Germany.  For each sample, the three groups of light 
standard, medium and heavy labelled protein content were mixed in ratios of 1:1:1 
then digested using trypsin. Titanium dioxide (TiO2) and phosphotyrosine antibodies 
were used to enrich global and tyrosine phosphorylated peptides, respectively. 
Afterwards, enriched phosphopeptides were fractionized using strong cation 
exchange (SCX) then applied on HPLC system coupled online to mass spectrometer.  
Raw data out of the mass spectrometer were analyzed through MaxQuant 
bioinformatics tool, while I used Perseus tool to perform the quality control and 
downstream differential analysis of the data. After filtering reverse and potential 
contaminant values, numeric Venn diagrams showed a total of 14014 quantified 
phosphosites in the global proteome group and a total of 831 quantified sites in the 
tyrosine enriched group (Figure 49).    
 
Figure 49: Numeric Venn diagram showed total number of quantified phosphosites among 
different groups. Phosphosites were quantified among two biological replicates and two 





With the purpose of assessing the quality of the replicates among different quantified 
groups, I used multiple scatter plot assigned with regression values (R), which 
showed similarities between different technical and biological? replicates in the 
GPome and pYome groups (Figures 50 and 51).  
 
 
Figure 50: Multiple scatter plot for all samples in global proteome phosphopeptides group. 
Quality of different replicates among global proteome phosphopeptides group was assessed through 
testing similarities between biological and technical replicates using regression number R in DMSO 







Figure 51: Multiple scatter plot for all samples in phospho-tyrosine enriched group. 
Regression values (R) showed quality of technical and biological replicates among tyrosine enriched 
phosphopeptides group in control group (A) and AZD4547 treated group (B).  
 
Thereafter, I tested the normal distribution of values among all technical and 
biological replicates in all the groups (Figures 52 and 53). Histograms showed 
normal distribution of the values, which enabled the progress to the next step in the 






Figure 52: Normal distribution of values in global proteome group. 
Histograms showed normal distribution of all values among all the technical and biological replicates in 







Figure 53: Normal distribution of values in phospho-tyrosine enriched group. 
Histograms showed the normality in distribution in technical and biological replicates of DMSO treated 
cells (A) and AZD4547 treated cells (B) in pYome group. 
 
3.3.3. Phosphoproteomic LC-MS/MS data bioinformatics functional analysis 
In order to perform statistical analysis tests, I calculated the average of technical 
replicates values and assigned the biological replicates in groups. Five groups where 
assigned as following: 1- H1581 (control group), 2- H1581 mutantAkt, 3- H520 (native 
resistant), 4- C9 (induced resistant) and 5-C11 (induced resistant). Sites were filtered 
for localization probability of more than 0.75 and 70% valid values. I performed 
multiple sample ANOVA test to compare all biological replicates among all groups 
together. The S0 parameter was set to zero, permutation-based FDR was chosen 
with FDR value of 0.05 and number of randomizations was set to 250.  
In total, 731 and 667 phosphosites were significantly regulated among the global 
proteome in DMSO and AZD4547 treated cells, respectively. Heatmaps of enriched 
significant phosphosites showed clustering between parental H1581 and H1581 
mutant-Akt on one side and between native resistant H520 and induced resistant C9 





three groups, the groups appeared to be as following: H1581 as first cluster, H1581-
mutantAkt as second cluster and H520, C9 and C11 as third cluster. In pYome 
groups, 34 and 86 phosphosites were significantly regulated among all groups in 
DMSO and AZD4547 treated cells, respectively. ANOVA significant enriched 
heatmaps showed again two main clusters. The first cluster consisted of H1581 
control and mutant-Akt cells. The second cluster consisted of H520, C9 and C11 cells 
(Figure 55). 
 
Figure 54: Heatmaps of significantly differentiated intensities of phosphosites among different 
GPome samples. 
Intensities of phosphosites were analyzed using ANOVA multiple test with FDR value of 0.05 in DMSO 
treated (A) and AZD4547 treated (B) cells of global proteome samples. Intensities were z-normalized 






Figure 55: Heatmaps of significantly differentiated intensities of phosphosites among different 
pYome samples. 
Intensities of phosphosites were analyzed using ANOVA multiple test with FDR value of 0.05 in DMSO 
treated (A) and AZD4547 treated (B) cells of tyrosine enriched phosphopeptides. Intensities were z-
normalized and imputated for missing values.  
 
Next, I compared intensities of phosphosites in each sample on its own to the control 
H1581 cell line. To achieve this, I used volcano plots and t-test with an FDR value of 
0.05, S0 of 0.1 and number of randomizations of 250. In the GPome analysis, the 
number of significantly differentially phosphorylated sites were 531, 293, 553 and 
1581 in the groups of mutantAkt, H520, C9 and C11, respectively. In the pYome 





and 75 in the groups of mutantAkt, H520, C9 and C11, respectively. (Figures 56 and 
57).  
 
Figure 56: Volcano plots show significantly differentiated phosphosites. 
Intensities of GPome phosphosites in the control H1581 cell line were compared to each of the H1581 
mutantAkt (A), H520 (B), C9 (C) and C11 (D) DMSO-treated cells. Figures show t-test with an FDR of 






Figure 57: Volcano plots of significantly differentiated phosphosites in pYome samples. 
Intensities of tyrosine enriched phosphosites in the control H1581 cell line were compared to each of 
the H1581 mutantAkt (A), H520 (B), C9 (C) and C11 (D) DMSO-treated cell lines. Figures show t-test 
with an FDR of 0.05 and S0 of 0.1. 
 
In order to investigate targets activation that could have led to FGFR1 inhibition 
resistance, I examined the lists of t-test and ANOVA significant sites among all the 
groups. Examination of the phosphosites depended on three main factors. The first 
factor is the clustering of phosphosites into H1581 sensitive parental cell line, H1581 





and C11 cell lines. The second factor is the functional annotation of each of the sites 
using DAVID, String and Gene cards databases. The last factor is the literature 
review where I checked for biological relevance of each of the sites as well as the 
interaction of these sites together. Using these three factors, I discovered a strongly 
significantly regulated pathway upstream of Akt, which is upregulated in the native 
and induced resistant cells but not in the mutant resistant cell line. The pathway 
consisted mainly of CD44, FAK, PAK1, Paxillin, RAC1, CDC42 and STAT3 proteins. 
At the same time, Akt and its downstream target, PRAS40, were significantly highly 
activated in all resistant cell lines compared to parental H1581 control (Figure 58). 
Further sites, which were significantly higher or lower activated in resistant cell lines 
compared to parental H1581 control can be connected to processes in the body like 
apoptosis inhibition, proliferation or survival promotion and metastasis induction 
(Figure 59). As a control, I demonstrated the efficacy of FGFR1 signaling inhibition 
via AZD4547 through the reduction of ERK inhibition at Y187 phosphosite (Figure 
58). 
 
Figure 58: Fold change of significantly over and down phosphorylated targets upstream and 





ANOVA significant targets are shown as fold change of the parental H1581 control cell line in the 
DMSO and AZD4547 treated conditions. ERK phosphotyrosine site at Y187 is shown as log2 value to 
demonstrate the efficacy of AZD4547 inhibition. 
 
 
Figure 59: Proposed resistance pathway in FGFR1 inhibition resistant cell lines compared to 
H1581 control cell lines. 
Effectors upstream of Akt were significantly differentiated in all resistant cells except of H1581 mutant-
Akt cell line, while effectors downstream of Akt were significant regulated in all resistant cells 





3.3.4. Functional validation of the proposed FGFR1 inhibition resistance 
pathway  
In an effort to functionally validate the new molecular targets in the resistance 
pathway, I treated the native resistant cell lines H520 and H1703 and the induced 
resistant clones C4, C9 and C11 with PAK1 or FAK inhibitors alongside with the 
FGFR1 inhibitor. Two highly specific PAK1 inhibitors were used. FRAX597 is an ATP 
competitive inhibitor of PAK1 with an IC50 value of 8 nM as reported by the provider 
(Selleck chemicals), while IPA-3 is a non-ATP competitive PAK1 inhibitor with an 
IC50 value of 2.5 µM as reported by the provider (Selleck chemicals). A single potent 
FAK inhibitor was used. PF562271 is a potent ATP competitive inhibitor of FAK with 
An IC50 of 1.5 nM as reported by the supplier (Selleck chemicals). 
AZD4547 was used as an FGFR1 inhibitor. The five cell lines were treated with 
elevated concentrations of either one of the inhibitors or both combined. Results of 
the combination therapy were measured through MTS colorimetric assay (Figures 60 
and 61). Nature of interaction between FGFR1 and PAK1 or FAK inhibitors was 
assessed through Chou-Talalay combination index (CI) across the cell lines. CI index 
showed strong synergistic effect between AZD4547 and each of FRAX579, IPA-3 






Figure 60: MTS assays show combination between PAK1 or FAK and FGFR1 inhibition in 
FGFR1 inhibition intrinsic resistant cell lines.   
Assay shows resistance to the FGFR1 inhibitor AZD4547 in all resistant cells (A). Combination 
inhibition between FGFR1 inhibitor (AZD4547) and PAK1 inhibitor (FRAX597) (B and E), PAK1 
inhibitor (IPA3) (C and F) and FAK inhibitor (PF562271) (D and G) in intrinsic resistant cell lines. 
Inhibitors were used at the concentrations denoted in the table above. All experiments were conducted 







Figure 61 MTS assays show combination between PAK1 or FAK and FGFR1 inhibition in 
FGFR1 inhibition induced resistant cell lines.   
Combination inhibition between FGFR1 inhibitor (AZD4547) and PAK1 inhibitor (FRAX597) (A, D and 
G), PAK1 inhibitor (IPA3) (B, E and H) and FAK inhibitor (PF562271) (C, F and I) in induced resistant 
clones. Inhibitors were used at the concentrations denoted in figure 60. All experiments were 








Figure 62: Synergistic effect between FGFR1 and PAK1 or FAK co-inhibition in FGFR1 
inhibition induced and intrinsic resistant cell lines. 
Combination index plots show the CI index, which correlates to the nature of interaction between the 
FGFR1 inhibitor (AZD4547) and PAK1 inhibitor (FRAX579), PAK1 inhibitor (IPA3) and FAK inhibitor 
PF562271. Fractions of dead cells (Fa) were measured by MTS assay. Combination indexes (CI) were 
calculated using CompuSyn software based on Chou-Talalay drug interaction algorithm. CI < 1 for 





In order to test the effect of FGFR1 and FAK co-inhibition on Akt activation, I blotted 
protein lysates from singly or doubly treated cells on nitrocellulose membranes and 
analyzed the fold change of Akt and PRAS40 phosphorylation compared to DMSO 
treated cells. Western blot showed reduction in Akt and PRAS40 (substrate of Akt) 
phosphorylation upon co-inhibition of FGFR1 and FAK compared to control cells 
(Figure 63). 
 
Figure 63: Immunoblotting for FGFR1 and FAK co-inhibition in resistant cells.  
Western blot shows levels of phosphorylated FGFR1, Akt and PRAS40 proteins under single inhibition 
of FGFR1 (0.9µM of AZD4547) and FAK (1.3µM of PF562271) or combination inhibition of both 
inhibitors. Charts show fold change of Akt and PRAS40 phosphorylation levels compared to the 
DMSO treated cells after normalizing to the housekeeping protein PARK7. 
 
Finally, to test the effect of combining CD44 knockdown with FGFR1 inhibition in 
resistant cells, I transfected the intrinsic and induced resistant cells with a functionally 
verified siRNA targeting CD44 or a scrambled siRNA. Western blot confirmed the 
efficiency of CD44 knockdown at 100nM. Afterwards, resistant cells were incubated 
with either DMSO and siControl, FGFR1 and siControl, DMSO and siCD44 or FGFR1 
and siCD44 for nine days. MTS proliferation assay showed significant reduction in 
proliferation of resistant cells under co-treatment with the FGFR1 inhibitor (AZD4547) 







Figure 64: Combination between FGFR1 inhibition and CD44 knockdown in FGFR1 inhibition 
resistant lung cancer cells.  
Combination between FGFR1 inhibition through AZD4547 and CD44 knockdown through a siRNA 
transfection. Experiments were conducted in triplicates. P values were denoted as * = p ≤0.05 and **** 






4.1. Molecular targets in lung cancer 
Lung cancer remains the primary cause of cancer related death worldwide (IARC, 
2018). Lack of early symptoms is a characteristic of lung cancer, which leads to 
diagnosis at late and metastatic stages. Widespread screening of high-risk groups 
has shown that only 15% of newly diagnosed patients had localized lung cancer 
tumors, while about 57% of the newly diagnosed patients suffered metastatic tumors 
(V. W. Chen et al., 2014). The five-year survival rate of metastatic lung cancer is only 
about 2-5% (Bozinovski et al., 2016; NIH, 2018). Aggressiveness and spread of lung 
cancer have limited the possibility of surgical intervention on the one hand, and 
required more effective therapy than conventional systemic chemotherapy on the 
other hand.  
Molecular therapy has arisen as the new promising cure for cancer in general and for 
lung cancer specifically. Molecular therapy depends on targeting molecular 
alterations (e.g., gene mutation, amplification and rearrangement) with specific drugs. 
The specificity of the drug to the molecular target alongside with the specificity of the 
molecular target to the tumor cells made this approach quite effective with minimal 
side effects (Kurzrock et al., 2020).  
Multiple specific targets have been discovered in lung cancer. The US Food and 
Drug Administration (FDA) has approved therapies against epidermal growth factor 
receptor (EGFR) mutations like Erlotinib, Afatinib and Gefitinib. Molecular therapies 
against ALK gene rearrangements like Crizotinib, Ceriitinib and Alectinib have been 
approved by the FDA as well (Travis et al., 2013). While the aforementioned 
molecular targets and therapies have proven effectiveness and improved patients’ 
prognosis, they all belong to only one class of lung cancer, which is adenocarcinoma 
(AC) of non-small cell lung cancer (NSCLC). Adenocarcinoma of the lung forms 
about 40% of all lung cancer histology. On the other side, squamous cell lung cancer 
(SQCLC, around 30% of lung cancer) and small cell lung cancer (SCLC, around 15% 
of lung cancer) completely lack approved molecular targets or molecular therapies 
(Arbour & Riely, 2019; Bozinovski et al., 2016; Zappa & Mousa, 2016). Collectively, 
previous reasons led to the urge to find new molecular targets in SQCLC and SCLC 





Fibroblast growth factor receptor 1 (FGFR1) gene amplification is an emerging 
promising molecular target in SQCLC and SCLC. New specific inhibitors (e.g., 
AZD4547 and BGJ398) have been developed to target FGFR1 amplification in 
designated lung cancer patients who harbor an FGFR1 gene amplification (Katoh, 
2019). Phase I and phase II clinical trials of the two inhibitors (AZD4547 and 
BGJ398) have proven safety and efficacy concept of these inhibitors in the 
designated patients. However, modest partial response results (7-11%) have raised 
questions about the appropriate patients’ selection criteria for these molecular targets 
and the resistance mechanisms that do exist in FGFR1 amplified patients or develop 
due to long drug exposure (Aggarwal et al., 2019; Nogova et al., 2017; Paik et al., 
2017).  
In this thesis, I try to improve the selection criteria for lung cancer patients who could 
benefit from FGFR1 specific inhibition. Moreover, I try to understand the molecular 
mechanisms that underline intrinsic and induced resistance to FGFR1 inhibition in 
SQCLC and SCLC cells with the aim of discovering new molecular targets that 
sensitize resistant cells. 
 
4.2. Studying prevalence of FGFR1 gene amplification in SQCLC 
and SCLC primary patient samples 
In order to use FGFR1 gene amplification as a molecular target in lung cancer, the 
amplification prevalence had to be widely screened and established among the 
patients. For this aim, a cohort of 421 lung cancer patient samples was collected. The 
cohort consisted of 208 patients diagnosed with SQCLC, 121 patients diagnosed with 
AC and 45 patients diagnosed with SCLC. FGFR1 gene amplification was tested 
using fluorescence in situ hybridization (FISH) technique. FISH analysis showed 23% 
and 8% prevalence of FGFR1 gene amplification in SQCLC and SCLC groups, 
respectively. The amplification prevalence in SQCLC and SCLC groups was 
comparable to previously publicized reports (15-22% in SQCLC and 5-8.7 in SCLC) 
(Monaco et al., 2016; Schultheis et al., 2014; Seo et al., 2014; Weiss et al., 2010). In 
AC group, FGFR1 gene amplification was not screened due to reported scarcity of 
FGFR1 amplification in this group (0-3%) (Cihoric et al., 2014; Elakad et al., 2020; 





Next, I correlated FGFR1 gene amplification levels in SQCLC and SCLC patients to 
patient’s overall survival. Kaplan-Meier curves showed that no significant correlation 
existed between the two factors (p-values = 0.726 and 0.689 in SQCLC and SCLC 
groups, respectively). Hence, FGFR1 gene amplification status cannot predict 
patients’ prognosis on its own.  These results confirmed previous studies, which have 
shown no correlation between FGFR1 amplification and survival in lung cancer 
patients (Heist et al., 2012; Kohler et al., 2012; Sasaki et al., 2012) over studies, 
which have shown significant correlation (Cihoric et al., 2014; Seo et al., 2014; Yang 
et al., 2013).  
 
4.3. Validating immunohistochemistry technique and antibody 
In the interest of screening FGFR1 gene expression among the lung cancer patient 
cohort, tissue microarrays of patient tissue samples were stained against FGFR1 
antibody using immunohistochemistry (IHC) technique. Immunohistochemistry is a 
robust diagnostic and prognostic technique in clinical pathology. Treatment strategies 
in different tumors can depend mainly on the results of IHC staining (e.g., ER-alpha 
and HER2 in breast cancer) (Bordeaux et al., 2010). However, the accuracy of the 
technique relies primarily on the specificity of the antibody used and the staining 
protocol. According to the FDA, validation of the antibody requires proving sensitivity, 
selectivity and reproducibility (Bordeaux et al., 2010). Therefore, the validation of the 
FGFR1 antibody and the staining technique was an essential step prior to screening 
FGFR1 expression prevalence. To validate the sensitivity of the FGFR1 antibody, I 
stained human tissues samples of tonsil and gallbladder and compared their results 
to literature. Tonsil tissue showed weak FGFR1 signal, while gallbladder tissue 
showed strong FGFR1 signal. These results correlated to published results in 
FANTOM5 and HPA databases (Lizio et al., 2015; Uhlen et al., 2015).  
To validate the selectivity of the antibody, I used CRISPR-Cas9 technique to knock 
out FGFR1 gene in H1703 SQCLC cell line. Two different guide RNAs (gRNAs) were 
designed to target and completely delete exon number 14 in FGFR1 gene causing a 
frameshift mutation and disruption of the protein. Success of the knockout was 
validated using Sanger sequencing and western blotting. Immunocytochemistry (ICC) 
staining of the control and the knockout H1703 cell line showed a complete negative 





4.4. Studying prevalence of FGFR1 expression in AC, SQCLC and 
SCLC primary patient samples 
The validated FGFR1 antibody was used to stain 171, 114 and 44 SQCLC, AC and 
SCLC patient tissue samples, respectively. IHC signals showed strong FGFR1 
expression in 9%, 35% and 4% in SQCLC, AC and SCLC samples, respectively. In 
the SQCLC group, FGFR1 protein expression was comparable to previously 
published results (i.e., 10% prevalence) (Kohler et al., 2012). In AC group, 35% 
FGFR1 expression prevalence was slight higher than previous reports (31%), while in 
SCLC group, previous reports have reported between 7.2 and 43.7% FGFR1 
expression (Kohler et al., 2012; Yang et al., 2013; L. P. Zhang et al., 2015). The 
variation of reported prevalence of FGFR1 expression could originate from 
differences in the antibody used, cutoff values for positive and negative results and 
patients characteristics (Elakad et al., 2020). 
Afterwards, I checked if FGFR1 expression level could have a prognostic value in the 
three tested lung cancer groups. Kaplan-Meier survival curves showed no significant 
correlation between FGFR1 expression levels and any of the tested groups with p-
values of 0.922, 0.724 and 0.443 in SQCLC, SCLC and AC groups, respectively. The 
results validated the non-significant correlation between FGFR1 protein expression 
and lung patients overall survival published before (Behrens et al., 2008; Heist et al., 
2012). 
 
4.5. Correlation between FGFR1 gene amplification and protein 
expression in lung cancer primary patient samples and cell 
lines  
In order to study FGFR1 gene amplification as a predictive biomarker for molecular 
target therapy in lung cancer, the correlation between FGFR1 gene amplification and 
protein expression has to be well understood. Investigating such correlation can help 
us indicate more accurate selection criteria for FGFR1 inhibition in clinical trials. 
FGFR1 gene amplification and protein expression were correlated in 129 SQCLC 
and 36 SCLC patient tissue samples as well as in 14 lung cancer cell lines. The 
correlation in patient samples was based on comparing FISH to IHC analyses. In the 





western blotting analyses. Chi-square test showed non-significant correlation 
between the two parameters with p-values of 0.54, 0.99 and 0.09 in SQCLC, SCLC 
and lung cancer cell lines, respectively. Again, these results do promote previous 
reports, which have shown no correlation between the two parameters over reports, 
which have shown significant correlation (Pros et al., 2013; von Massenhausen et al., 
2013; Y. Wang et al., 2015). 
While clinical trials of FGFR1 inhibitors have relied mainly on FGFR1 amplification 
and not expression as patients’ selection criteria, the inconsistency between the two 
parameters could account for the modest results that were observed in these trials. 
 
4.6. Building a lung cancer cell lines model to study mechanisms 
of FGFR1 inhibition resistance  
In order to study the native or intrinsic resistance mechanisms against FGFR1 
inhibition, an appropriate cell lines model had to be established. The first 
characteristic of the model is that it contains sensitive and resistant cell lines to 
FGFR1 inhibition. To test sensitivity to FGFR1 inhibition, 21 lung cancer cell lines 
were incubated with increasing concentrations of the FGFR1 inhibitor AZD4547 for 
96 hours. Viability of the cells was measured through MTS assay. Cell lines 
represented the three histological types: squamous cell lung cancer, small cell lung 
cancer and large cell lung cancer. These types of lung cancer were selected as they 
constitute the main histological types of lung cancer that are being targeted by 
FGFR1 inhibitors (Paik et al., 2017).  
The study model included cell lines harboring FGFR1 gene amplification and strong 
protein expression, which formed the testing group. In the control group, two lung 
cancer cell lines were used, which did not harbor FGFR1 gene amplification or strong 
protein expression. To test FGFR1 gene amplification in the cell lines, they were 
embedded into cell blocks and then stained against the FGFR1 gene and centromere 
8 as a control and tested through FISH technique. FISH technique was chosen to test 
for FGFR1 gene amplification as this technique is considered the regular gene 
amplification diagnostic technique for patients’ tissue samples in routine diagnostics. 
FISH analysis showed that the cell lines: H520, H1703, DMS114 and H1581 were 





were negative. FISH analysis results were supported by previous analyses, which 
have shown the same amplification scheme among the seven cell lines using real-
time PCR and single nucleotide polymorphism (SNP) array based gene copy number 
assays (Dutt et al., 2011; Guffanti et al., 2017).  
FGFR1 protein expression levels were assayed through western blotting and 
immunocytochemistry using two different anti-FGFR1 antibodies. FGFR1 expression 
level analyses showed that H1703, H520, H1581, DMS114 and LK2 cell lines 
demonstrated strong expression of FGFR1 protein, while HCC15 and H2170 cell 
lines demonstrated very weak FGFR1 expression. These findings were supported by 
previous studies, which assayed mRNA expression levels using real-time PCR and 
protein levels using western blotting (Dutt et al., 2011; Rooney et al., 2016). 
 Correlating FGFR1 gene amplification level and protein expression level, I found that 
LK2 cell line showed normal gene copy number and strong FGFR1 protein 
expression at the same time. FGFR1 protein expression of LK2 cell line was 
comparable to other cell lines with high FGFR1 gene copy number amplification. The 
inconsistent correlation between FGFR1 gene amplification and protein expression 
supports the previously discussed correlation in primary patient samples. 
Interestingly, MTS viability assay showed that LK2 cell line is a highly sensitive cell 
line to FGFR1 inhibition with an IC50 < 100 nM. Sensitivity of LK2 cell line to FGFR1 
inhibition suggests that FGFR1 protein expression could shape a more accurate 
selection criteria for FGFR1 inhibition than gene amplification. Hence, lung cancer 
patients without FGFR1 amplification could benefit from FGFR1 inhibition therapy if 
they harbor FGFR1 strong protein expression. 
 
4.7. Validation of AZD4547 tyrosine kinase inhibition activity and 
specificity to FGFR1 
Despite high specificity reported of AZD4547 as an FGFR1 inhibitor, it was essential 
to expand validation of the model’s response pattern beyond a single inhibitor. 
BGJ398 is a selective pan-FGFR1 inhibitor developed by Novartis (Katoh, 2019). To 
validate the sensitivity scheme of the cell lines in my model to FGFR1 inhibition, I 
treated the cell lines with the FGFR1 specific inhibitor BGJ398 for 96 hours and 





AZD4547 inhibition were comparable to those under BGJ398 inhibition, which 
validated the sensitivity scheme of the cell lines in the model. AZD4547 and BGJ398 
inhibitors showed that H1581, DMS114 and LK2 cell lines are highly sensitive to 
FGFR1 inhibition with IC50 < 100 nM. On the other side, H1703, H520, HCCC15 and 
H2170 cell lines are insensitive to the inhibition with IC50 > 5 µM. These results 
confirmed findings of other reports, which tested the sensitivity of the mentioned cell 
lines to FGFR1 inhibition (S. M. Kim et al., 2016; Kotani et al., 2016; Malchers et al., 
2017). Sensitivities of cell lines to FGFR1 inhibition were measured using two 
different viability assays (MTS assay and Muse viable cell count assay).  
Receptor tyrosine kinase inhibitors are prone to a degree of unspecific effects due to 
off-target inhibition. To ensure that the response pattern of my model reflected their 
dependency on FGFR1 signaling rather than other targets, I knocked down FGFR1 
via small interfering RNA (siRNA). FGFR1 knockdown was evaluated through 
western blotting using anti-FGFR1 antibody. Cell proliferation assay showed 
significant reduction in proliferation of DMS114, H1581 and LK2 cell lines during fifth 
and sixth days compared to scrambled control siRNA group. On the other side, 
proliferation of control-siRNA and FGFR1-siRNA groups in HCC15, H2170, H1703 
and H520 cell lines were comparable. FGFR1 knockdown results suggested that the 
sensitivity scheme of the tested cell lines originated from their dependence on 
FGFR1 signaling rather than on unspecific effects of the inhibitors used.  
 
4.8. Activated signaling pathway in sensitive and resistant cell 
lines to FGFR1 inhibition 
Under normal healthy conditions, FGFR1 regulates vital processes in the body like 
cell proliferation, differentiation and survival. FGFR1 controls these functions through 
regulating the activation of three main pathways: MAPK-ERK, PI3K-Akt and JAK-
STAT pathways (Malchers et al., 2017). Dysregulation of these main pathways is 
responsible not only for tumorigenesis induced by FGFR1, but also for resistance to 
FGFR1 inhibition (Kotani et al., 2016). In order to understand regulation of the main 
pathways in FGFR1 signaling under sensitive and resistant conditions, cellular 
lysates of DMSO or AZD4547 treated cell lines were blotted on membranes and 
stained against the main effectors in FGFR1 signaling. Treatment with 0.5 µM 





tyrosine site number 654 (Y654), which validated the function of the inhibitor. Efficacy 
of FGFR1 inhibition through AZD4547 was further validated through the reduction of 
activated MEK and ERK signals in sensitive and resistant cell lines while total un-
phosphorylated MEK and ERK signals remained unchanged. The main difference 
between FGFR1 signaling in sensitive and resistant cell lines was seen in the Akt 
pathway. The two resistant cell lines (H520 and H1703) showed highly activated 
signals of Akt at sites of Serine 473 (Ser473) and Threonine 308 (Thr308), while total 
Akt remained comparable among all cell lines.  
To extend the analysis of FGFR1 signaling in sensitive and resistant cell lines, levels 
of RNA expression were analyzed through Archer FusionPlex CTL Panel®. Archer 
CTL panel is a site directed RNA sequencing technique, which tests the expression 
levels of 36 genes associated with lung and thyroid cancers (Benayed et al., 2019; 
Chang et al., 2019). RNA sequencing showed that the main difference between the 
three groups of cell lines (control, sensitive and resistant groups) was the elevated 
expression levels of FGFR1 in resistant and sensitive cells compared to control cells. 
The second observation out of the RNA sequencing analysis was the significant 
elevation of Akt1 signal in H520 resistant cell line and the slight elevation of the same 
signal in H1703 resistant cell line compared to the three cell lines in the sensitive 
group. While western blot analysis showed uniformity between total Akt signals in all 
cell lines, RNA sequencing showed elevated RNA expression of Akt1 in resistant cell 
lines. This apparent conflict could be explained by the specificity of the RNA 
sequencing to Akt1 expression, while the antibody used in western blotting was a 
pan-Akt antibody, which binds to all Akt isoforms (Akt1, Akt2 and Akt3). The last 
observation of the RNA sequencing analysis was the absence of any other significant 
distinction between the sensitive and resistant groups in any of the 36 genes 
associated with lung and thyroid cancers. 
Collectively, signaling pathway analyses between sensitive and resistant cell lines 
suggested that Akt activation could play an important role in the resistance to FGFR1 
inhibition. Akt pathway is a main survival pathway, which regulate basic functions in 
the cells like cell proliferation, apoptosis, gene transcription and cell migration. These 
processes construct the main players in developing any resistance against general or 
directed therapies (Huang & Hung, 2009). Consequently, in tumor treatment, 





DNA-targeted therapy resistance and directed small molecule inhibitors resistance 
(Avan et al., 2016; Cassinelli et al., 2013; Huang & Hung, 2009; Jacobsen et al., 
2017). 
 
4.9. Activation of Akt in FGFR1 amplified and FGFR1-expressing 
primary SQCLC tissue samples  
To check if Akt overactivation is a real event that takes place in primary patient 
samples and not an exclusive behavior of cell lines, I stained 32 FGFR1-amplified 
and 45 FGFR1- expressing SQCLC primary tissue sample for pAkt (Ser473). 
Immunohistochemistry analysis (through H-score system) showed wide range of 
variation in Akt phosphorylation among patient samples. Some patients completely 
lacked any phosphorylation of Akt (H-score = zero), while other patients showed 
strong phosphorylation of Akt (H-score = 300). The majority of patients ranged 
between the two margins. This finding does add weight to the proposed role of Akt 
activation in FGFR1 inhibition resistance. Nevertheless, these patients were not 
treated with FGFR1 inhibitors, hence a direct connection between Akt activation level 
and patients’ response to FGFR1 inhibition could not be concluded from this data. 
 
4.10. Combining FGFR1 and Akt inhibition to sensitize resistant 
cells to FGFR1 inhibition 
In cancer treatment, combination therapy is a major module where patients are 
treated with more than one therapy simultaneously. Combined therapies are usually 
accompanied by better prognosis and outcome for two main reasons. Firstly, the 
synergistic or additive effect of the two therapies is stronger than the monotherapy. 
Secondly, combined therapies can compensate for patient-to-patient variability 
(Palmer & Sorger, 2017). In specific targeted drugs, combined therapies usually 
target the same pathway or a resistance pathway of the leading therapy. 
Combination therapy usually utilizes one or more FDA approved therapies together, 
hence increasing efficiency of treatment and reducing time needed for approvals at 
the same time (Bayat Mokhtari et al., 2017). Accordingly, combining Akt inhibition to 
FGFR1 inhibition could have a synergistic effect, inhibit the resistance pathway and 





In order to test the effect of combining Akt and FGFR1 inhibition, I treated the FGFR1 
inhibition resistant cell lines (H520 and H1703) with both AZD4547 (FGFR1 inhibitor) 
and AZD5363 (Akt inhibitor) simultaneously. AZD5363 is an ATP-competitive Akt 
inhibitor, which is currently in phase II clinical trials (Banerji et al., 2018; Schmid et 
al., 2018). MTS viability assay showed a strong and significant reduction of resistant 
cells’ viability under the combined therapy. To test the interaction between the two 
inhibitors, I used the Chou-Talalay combination index (CI). Chou-Talalay method for 
calculating multiple drugs interactions is a widely recognized and validated method, 
which is based on median-effect equation and can differentiate between synergistic, 
additive and antagonistic effects represented by CI < 1, CI = 1 and CI > 1, 
respectively (Chou, 2006, 2010). CI indexes showed strong synergistic effects 
between FGFR1 and Akt inhibitors in the resistance cell lines.  
These results proposed a hypothesis, which states that Akt activation is an intrinsic 
resistance mechanism in FGFR1-amplified SQCLC lung cancer cells to FGFR1 
inhibition. In other words, high level of Akt activation does pre-exist in some lung 
cancer cells before receiving any FGFR1 inhibition. Cells with high Akt activation are 
resistant to FGFR1 inhibition and could be targeted using Akt inhibitors combined 
with FGFR1 inhibitors.  
 
4.11. Inducing Akt activation in sensitive lung cancer cell lines to 
FGFR1 inhibition 
To validate the tendency of Akt activation to induce FGFR1 inhibition resistance, I 
transfected the three sensitive cell lines (H1581, DMS114 and LK2) with 
constitutively active Akt plasmids. The plasmids do express myristoylated Akt (Myr-
Akt), which is based on attachment of a myristoyl group (lipid group) to the Akt 
leading to its localization to the cell membrane and hence activation (Kohn et al., 
1996). Overactivation of Akt was validated by western blotting, which showed high 
elevation of pAkt at Ser473 in H1581 cell line, medium elevation in pAkt signal in LK2 
cell line, while DMS114 cell line showed only minimal activation of Akt. MTS viability 
assay revealed that overactivation of Akt significantly induced FGFR1 inhibition 
resistance compared to controls. Resistance of mutant-Akt cells was the highest in 
H1581 followed by LK2, while DMS114 did not show difference in the response to 





could be attributed to the magnitude of mutant-Akt activation in these cells shown by 
western blotting. Again, combination inhibition between Akt and FGFR1 inhibitors 
succeeded to synergistically reverse the resistance induced by activated Akt and 
reduce cells’ viability in H1581 and DMS114 cell lines after treatment.  
 
4.12. Induction of FGFR1 resistance in FGFR1 inhibition sensitive 
batch cell lines  
Tumor cells are in a constant movement to induce their proliferation, reduce their cell 
death and compensate for essential pathways inhibited by any therapeutic elements. 
This movement leads cancer cells to acquire resistance against targeted drugs after 
long exposure. Resistance induced in cancer cells due to long exposure to treatment 
is defined as induced or acquired resistance (Holohan et al., 2013). Another 
hypothesis does exist, which explains the mechanism of acquired resistance slight 
differently. The hypothesis describes tumors as huge group of heterogeneous cells, 
which could contain very few cells that are originally resistant to the therapeutic 
agent. These few or single resistant cells get selected under long incubation period of 
the therapeutic agent (Holohan et al., 2013; Xuan Wang et al., 2019). 
In order to study induced resistance to FGFR1 inhibition in my model, I exposed the 
three sensitive cell lines (H1581, DMS114 and LK2) to the FGFR1 inhibitor 
(AZD4547) for four months. MTS viability assay validated the high level of resistance 
induced in the originally sensitive cell lines to FGFR1 inhibition. To test the activated 
signaling pathways in the induced resistance cell lines, protein lysates of the cell lines 
were blotted on membranes and analyzed through western blotting technique. The 
immunoblotting was repeated at least three times for each of the cell lines with 
different biological replicates. Results showed large diversity in the ERK-MAPK and 
PI3K-Akt pathways between each of the replicates. I attributed the inconsistency of 
the activated signaling pathways between the replicates to the cell lines batch-effect. 
Batch-effect meant that each of the cell lines enclosed heterogeneous group of cells 
with different mechanisms of resistance developed and fluctuated inside. The 
versatile mechanisms of acquired resistance developed in a single lung cancer cell 
line have been shown before in adenocarcinoma targeted with EGFR inhibitors 





4.13. Inducing FGFR1 resistance in single clones of FGFR1 
inhibition sensitive cell lines 
In order to surpass the batch-effect of acquired resistance cell lines, I sorted H1581, 
DMS14 and LK2 cell lines into single clones and then treated them with rounds of 
high concentration of FGFR1 or fresh growth medium. Due to high vulnerability of 
single cells, the process of resistance induction lasted for ten months. A total of 14, 
17 and 17 resistant single clones were successfully obtained from H1581, DMS114 
and LK2 cell lines, respectively.  Western blot analysis did confirm the variation in 
activated signaling pathways in resistant single clones, which shared a parental cell 
line. Akt activation was found in 21.4%, 29.4% and 5.9% in H15851, DMS114 and 
LK2 single clones compared to parental controls, respectively. On the other side, 
ERK activation was found in 14.3%, 5.9% and 25.5% in H15851, DMS114 and LK2 
single clones compared to parental controls, respectively.  
Combining Akt inhibition and FGFR1 inhibition, successfully and significantly 
sensitized the three H1581 resistant single clones with Akt activation (clones 4, 9 and 
11) to FGFR1 inhibition using two different viability assays. Chou-Talalay analysis 
showed the interaction between FGFR1 and Akt inhibitors to be a strong synergistic 
interaction (CI = 0.1 – 0.03). 
To analyze signaling pathways in the three resistant single clones (C4, C9 and C11), 
expressed RNA levels were measured using Archer CTL directed panel and protein 
levels were assayed using western blotting. On RNA expression level, RNA 
sequencing showed upregulation in FGFR1 expression and downregulation of GNAS 
to be the only two significant differences between resistant clones and their parental 
control cell line.  
On protein level, western blotting confirmed the activation of Akt in the three clones 
(at least at Ser473 site). Literature show that a decline in PTEN levels (an Akt 
suppressor) is usually accompanied by elevation of Akt activation, which was the 
case in C9 and C11 resistant clones (Georgescu, 2010). Interestingly, PTEN levels in 
C4 clone were comparable to the parental H1581 cell line. Western blotting showed 
that treatment with 0.5 µM AZD4547 was sufficient to inhibit phosphorylation of 
FGFR1 (Y653/Y654) in the parental cell line as well as the three single clones 





reason behind FGFR1 inhibition resistance in the three single clones, which added 
more weight to the role of Akt overactivation in inducing the resistance. 
PRAS40 (Akt1S1), an important substrate of Akt and a subunit of mTOR complex 1 
(mTORC1), is a downstream effector of Akt with strong tumor proliferative and 
survival capabilities (Lv et al., 2017; Qi et al., 2020). PRAS40 was strongly activated 
in all of the three resistant clones. On the other side, MEK signals were activated only 
in C4 clone and largely inhibited in C9 and C11 clones compared to parental control. 
Likewise, activated ERK signals were lost in C9 and C11 clones but not in C4 clone 
compared to parental control. Taken together, western blot analysis suggested that 
C4, C9 and C11 clones gained their resistance to FGFR1 inhibition through activating 
the Akt-PRAS40 survival pathway.  
 
4.14. Sample preparation for LC-MS/MS phosphoproteomic 
analysis in FGFR1 inhibition resistant lung cancer cell lines  
Liquid chromatography coupled to mass spectrometry (LC-MS/MS) is a robust 
quantitative method that can accurately measure levels of proteins in tested samples. 
Applying LC-MS/MS to tumor research can help allocating signaling pathways 
responsible for tumor initiation, progression, metastasis as well as resistance to 
tumor therapies (Bohnenberger et al., 2018; Corso et al., 2016). Analyzing protein 
levels in tumor cells reveals more information on the functional level than analyzing 
DNA and RNA nucleic acid levels. Enriching the proteomic analysis for 
phosphorylated proteins can help us to precisely understand functional activated and 
deactivated specific signaling pathways in tumor cells (H. Wang et al., 2016).  
In the current project, I used LC-MS/MS phosphoproteomic analysis in order to 
identify resistance mechanisms to FGFR1 inhibition in lung cancer cells with the aim 
of finding new molecular targets that could sensitize resistant cells. The 
phosphoproteomic analysis was carried out with a special focus on validating and 
stratifying Akt pathway activation as a resistance pathway. I designed the model to 
include one control cell line and three groups of resistant cell lines. Firstly, H1581 
parental cell line was analyzed as the parental sensitive control cell line. Secondly, 
H520 cell line was used as an intrinsic or native resistant SQCLC cell line. Thirdly, 





Finally, H1581 resistant clones C9 and C11 were used as induced resistant cell lines. 
Clones number 9 and 11 were specifically selected from H1581-induced resistance 
clones as they showed elevation in Akt activation compared to the parental cell line. 
The aforementioned model structure, with the help of the mutant-Akt cell line, was 
able to not only differentiate between resistance mechanisms in native and induced 
cell lines, but also between activated signaling pathways upstream and downstream 
of Akt. 
For the aim of exploring the direct effect of AZD4547 inhibition, all cell lines were 
analyzed under control conditions (DMSO-treated) and under FGFR1 inhibition 
conditions (AZD4547-treated). DMSO-treated cells were cultured in medium heavy 
SILAC medium, while AZD4547-treated cells were cultured under heavy heavy 
SILAC medium. To control the quantification of DMSO and AZD4547 treated cells, 
we created a super-SILAC control. Super-SILAC control is composed of a mixture of 
different cell lines from the same tumor type mixed in equal ratios. The mixture of cell 
lines can more accurately represent the proteome of the tumor than a single cell line 
and hence improves the overall quantification accuracy (Geiger et al., 2010). To 
create a super-SILAC control, cell lysates out of four lung cancer cell lines were 
mixed in equal ratios and cultured in normal growth medium (light medium). 
Moreover, cell lysates were divided into two groups: global proteome group (GPome) 
for the global phosphorylated peptides and tyrosine-enriched group (pYome) for 
mainly tyrosine phosphorylated peptides. 
 
4.15. Quality control of LC-MS/MS phosphoproteomic analysis 
results 
To analyze the MS data, I used the Perseus software (version: 1.6.10.43), which is 
an open source mass spectrometry analysis tool (Tyanova & Cox, 2018; Tyanova et 
al., 2016). Numeric Venn diagrams showed that numbers of quantified 
phosphopeptides, in GPome group, were 6044, 6476, 5650, 6088 and 6032 in 
H1581, mutant-Akt, H520, C9 and C11 cell lines, respectively. In pYome group, 
quantified phosphopeptides were 312, 364, 310, 290 and 192 in H1581, mutant-Akt, 
H520, C9 and C11 cell lines, respectively. In total, 14014 different phosphosites were 





the pYome group. These high counts of successfully quantified phosphosites on the 
one side reflected good quality of sample preparation and of data in general and on 
the other side allowed for more chance of low abundant proteins’ quantification 
(Haupl et al., 2019).  
In GPome group, one technical replicate from each biological replicate of C9 cell line 
showed reduced counts of quantified cites, which was compensated through 
calculating the average of both technical replicates during the analysis. In pYome 
group, one technical replicate of only one biological replicate of C11 cell line showed 
reduced counts of sites, which was compensated through calculating the average of 
both technical replicates. 
Multi-scatter plots showed that coefficient of determination (R squared) between 
biological replicates in the GPome group to range between 0.7 and 0.8 except for 
H520 cell line in DMSO-treated group (0.4) and C9 cell line in AZD4547-treated 
group (0.5). In pYome group, R squared values between biological replicates ranged 
between 0.7 and 0.9 except for H520 cell line in DMSO-treated group (0.5) and C9 
cell line in AZD4547-treated group (0.6). The aforementioned R squared values 
showed that the quality of the biological replicates was good and the replicates could 
be used in functional analyses.   
Statistical analysis using ANOVA significance test showed 731 and 667 phosphosites 
to be significantly differentially phosphorylated between the five groups tested in the 
DMSO-treated and the AZD-treated GPome groups, respectively. In the pYome 
analysis, ANOVA analyses showed 34 and 86 sites to be significantly different 
between the five groups tested in DMSO-treated and AZD4547-treated groups, 
respectively. Histograms in GPome and pYome groups showed the majority of 
quantified proteins to have narrow distribution, which represented the advantage of 
using a super-SILAC standard.  
 
4.16. Activated signaling pathways among different models of 
FGFR1 inhibition resistant lung cancer cell lines 
Heatmaps of significantly differentiated phosphosites between all biological replicates 
showed on the one side high quality of the biological replicates and on the other side 





clearly showed the first degree of similarity to be between the two induced resistant 
clones C9 and C11. The second degree of similarity was between induced (C9 and 
C11) and intrinsic (H520) resistant cells compared to H1581 control and mutant-Akt 
cell line. The large degree of similarity in phosphoproteomic profiles of H1581-C9, 
H1581-C11 and H520 cells supports the existence of a common mechanism of 
resistance to FGFR1 inhibition in lung cancer. Moreover, the latter degree of 
similarity could be interpreted, to a certain limit, as the difference between upstream 
and downstream activation of Akt due to its distinction from mutant-Akt cell line. 
I examined functional annotations of the significant phosphosites using databases of 
Sring, DAVID and Gene cards (Dennis et al., 2003; Fishilevich et al., 2016; 
Szklarczyk et al., 2019). Moreover, I explored the literature to check for the relevance 
of these sites in tumor biology. Bioinformatics analysis along with literature review 
revealed a strong enriched pathway in resistant cell lines compared to the control cell 
line. Phosphorylation of CD44 at S706 (> 30-fold), FAK at Y576 (> 4-fold), PAK1 at 
S174 (> 10-fold), Paxillin at S119 (> 2-fold), Afadin at S1182 (> 2-fold) and reduction 
of Fyn phosphorylation at Y222 (> 2-fold) phosphosites formed the core of the 
resistance pathway, upstream Akt, in intrinsic and induced resistant cells compared 
to parental H1581 and mutant-Akt cell lines.   
CD44 is a transmembrane adhesion glycoprotein that regulates essential cellular 
functions like cell division, migration and cell-cell signaling (Basakran, 2015). 
Inhibiting CD44 expression has reduced tumor cells proliferation, metastasis and 
increased chemosensitivity and apoptosis in hepatocellular carcinoma, breast cancer 
and lung cancer (Basakran, 2015; X. Liu et al., 2019; Xie et al., 2008). In breast 
cancer, CD44 was shown to induce circulating tumor cells (CTC)-mediated 
metastasis through activation of PAK 1/2, FAK and Paxillin proteins (X. Liu et al., 
2019). On the other side, PAK1 (p21-activated kinase 1) is a member of 
serine/threonine kinase family, which consists of six members (PAK1-6) (Wu et al., 
2016). PAK1 regulates vital processes in the cells like cytoskeleton remodeling, 
proliferation and survival (Wu et al., 2016). Overexpression and overactivation of 
PAK1 has been reported in lung, brain, live and kidney tumors (Wu et al., 2016; Ye & 
Field, 2012). Activity of PAK1 protein is regulated through Akt, Cdc42 and Rac 





To study resistance-signaling pathways downstream of Akt, I compared the H1581 
parental control cell line to all resistant cell lines (including mutant-Akt H1581). 
Comparison showed activation of different targets responsible for processes of 
apoptosis inhibition (DAXX, ACIN1, BIM, AVEN and TSC22), promotion of 
proliferation and survival (SOX2, GAPDH and LMo7) and induction of migration and 
metastasis (ANXA1 and cortactin). Overactivation of Akt1 at S124 and its 
downstream effector PRAS40 at T246 were among overactivated proteins in all 
resistant cell lines compared to H1581 control cell line. (L. Y. Chen & Chen, 2003; 
Colell et al., 2007; de Graauw et al., 2010; Dennis et al., 2003; Eissmann et al., 2013; 
Fishilevich et al., 2016; Szklarczyk et al., 2019) 
 
4.17. Validation of PAK1 and FAK as a molecular targets in 
intrinsic and induced FGFR1 resistant lung cancer cell lines 
Phosphoproteomic analysis presented a core resistance pathway in intrinsic and 
induced resistant lung cancer cell lines to FGFR1 inhibition. Multiple novel drug 
targets within the resistance pathway could be tested and validated for their ability of 
sensitizing lung cancer resistant cells to FGFR1 inhibition. While the only current, 
direct and selective way to inhibit CD44 is through genetic knockdown, some 
selective inhibitors are available to target PAK1 and FAK proteins. I used FRAX579 
(ATP competitive), IPA-3 (non-ATP competitive) and PF562271 (ATP competitive) 
selective inhibitors to inhibit PAK1 and FAK in induced resistant cell lines (C4, C9 
and C11) as well as in the intrinsic resistant cell lines H520 and H1703. MTS viability 
assay accompanied by Chou-Talalay combination index showed synergistic effect 
between PAK1, FAK and FGFR1 inhibition in all tested resistant cell lines. Likewise, 
combination between CD44 knockdown and FGFR1 inhibition showed significant 
reduction in proliferation of resistant cells compared to single treatments. These 
results suggested that PAK1, FAK and CD44 are potential novel therapeutic targets 
in FGFR1 inhibition resistant lung cancer cells. 
 
4.18. Conclusion 
In the current thesis, FGFR1 gene amplification and protein expression prevalence 





revealed 23% and 8% prevalence of FGFR1 amplification in SQCLC and SCLC 
groups, respectively. IHC analysis revealed 9%, 4% and 23% prevalence of FGFR1 
protein expression in SQCLC, SCLC and AC lung cancer patients, respectively. 
Correlating FGFR1 gene amplification and protein expression among the same sets 
of patients showed non-significant correlation. Hence, the choice of FGFR1 gene 
amplification as the selective criteria for FGFR1 inhibitors in lung cancer patients 
should be reconsidered. Signaling pathway analyses between FGFR1-inhibition 
sensitive lung cancer cell lines on the one side and intrinsic or induced resistant cell 
lines on the other side showed Akt activation as a significant difference between the 
two groups. Functional viability assays confirmed synergy effect between FGFR1 
inhibitors and Akt inhibitors in FGFR1 inhibition resistant lung cancer cell lines. LC-
MS/MS phosphoproteomic analysis showed that over phosphorylated CD44, PAK1, 
FAK, Afadin, Paxillin and Akt formed a common resistance pathway in native and 
acquired resistant lung cancer cells to FGFR1 inhibition. Chou-Talalay combination 
index analysis confirmed synergy effect between FGFR1 inhibition combined with 
PAK1 or FAK inhibition in intrinsic and induced resistant lung cancer cells. CD44 
knockdown showed ability to significantly reduce proliferation of resistant cells only 
when combined with FGFR1 inhibition. Collectively, Akt, PAK1, FAK and CD44 
present interesting molecular targets to sensitize resistant lung cancer cells to 
FGFR1 inhibition.   
 
4.19. Outlook 
Future experiments should focus on five main lines of study. Firstly, studies should 
focus on validation of multiple molecular targets found in the resistance pathway like 
Afadin and Paxillin as sensitizers of lung cancer resistant cells to FGFR1 inhibition. 
Secondly, interaction between the main effectors in the resistance pathway (e.g., 
interaction between CD44 and PAK1 and Akt) should be validated in the resistant 
cells. Thirdly, in vivo models should be used to test and validate the synergistic effect 
of combining PAK1, FAK and Akt inhibitors to FGFR1 inhibitors in resistant lung 
cancer cells. Fourthly, phosphorylation levels of CD44, PAK1, FAK and Akt should be 
screened in SQCLC lung cancer patient samples who were treated with FGFR1 





should test the combination between Akt, PAK1 and FAK inhibitors and FGFR1 
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